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A B S T R A C T
Background
Schizophrenia and related disorders such as schizophreniform and schizoaffective disorder are serious mental illnesses characterised by
profound disruptions in thinking and speech, emotional processes, behaviour and sense of self. Clozapine is useful in the treatment
of schizophrenia and related disorders, particularly when other antipsychotic medications have failed. It improves positive symptoms
(such as delusions and hallucinations) and negative symptoms (such as withdrawal and poverty of speech). However, it is unclear what
dose of clozapine is most effective with the least side effects.
Objectives
To compare the efficacy and tolerability of clozapine at different doses and to identify the optimal dose of clozapine in the treatment
of schizophrenia, schizophreniform and schizoaffective disorders.
Search methods
We searched the Cochrane Schizophrenia Group’s Study-Based Register of Trials (August 2011 and 8 December 2016).
Selection criteria
All relevant randomised controlled trials (RCTs), irrespective of blinding status or language, that compared the effects of clozapine at
different doses in people with schizophrenia and related disorders, diagnosed by any criteria.
Data collection and analysis
We independently inspected citations from the searches, identified relevant abstracts, obtained full articles of relevant abstracts, and
classified trials as included or excluded. We included trials that met our inclusion criteria and reported useable data. For dichotomous
data, we calculated the relative risk (RR) and the 95% confidence interval (CI) on an intention-to-treat basis based on a random-effects
model. For continuous data, we calculated mean differences (MD) again based on a random-effects model. We assessed risk of bias for
included studies and created ’Summary of findings’ tables using GRADE.
Main results
We identified five studies that could be included. Each compared the effects of clozapine at very low dose (up to 149 mg/day), low
dose (150 mg/day to 300 mg/day) and standard dose (301 mg/day to 600 mg/day). Four of the five included studies were based on a
small number of participants. We rated all the evidence reported for the main outcomes of interest as low or very low quality. No data
were available for the main outcomes of global state, service use or quality of life.
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Very low dose compared to low dose
We found no evidence of effect on mental state between low and very low doses of clozapine in terms of average Brief Psychiatric Rating
Scale-Anchored (BPRS-A) endpoint score (1 RCT, n = 31, MD 3.55, 95% CI −4.50 to 11.60, very low quality evidence). One study
found no difference between groups in body mass index (BMI) in the short term (1 RCT, n = 59, MD−0.10, 95% CI−0.95 to 0.75,
low-quality evidence).
Very low dose compared to standard dose
We found no evidence of effect on mental state between very low doses and standard doses of clozapine in terms of average BPRS-A
endpoint score (1 RCT, n = 31, MD 6.67, 95% CI−2.09 to 15.43, very low quality evidence). One study found no difference between
groups in BMI in the short term (1 RCT, n = 58, MD 0.10, 95% CI −0.76 to 0.96, low-quality evidence)
Low dose compared to standard dose
We found no evidence of effect on mental state between low doses and standard doses of clozapine in terms of both clinician-assessed
clinical improvement (2 RCTs, n = 141, RR 0.76, 95% CI 0.36 to 1.61, medium-quality evidence) and clinically important response as
more than 30% change in BPRS score (1 RCT, n = 176, RR 0.93, 95% CI 0.78 to 1.10, medium-quality evidence). One study found
no difference between groups in BMI in the short term (1 RCT, n = 57, MD 0.20, 95% CI −0.84 to 1.24, low-quality evidence).
We found some evidence of effect for other adverse effect outcomes; however, the data were again limited.
Very low dose compared to low dose
There was limited evidence that serum triglycerides were lower at low-dose clozapine compared to very low dose in the short term (1
RCT, n = 59, MD 1.00, 95% CI 0.51 to 1.49).
Low dose compared to standard dose
Weight gain was lower at very low dose compared to standard dose (1 RCT, n = 27, MD −2.70, 95% CI −5.38 to −0.02). Glucose
level one hour after meal was also lower at very lose dose (1 RCT, n = 58, MD −1.60, 95% CI −2.90 to −0.30). Total cholesterol
levels were higher at very low compared to standard dose (1 RCT, n = 58, n = 58, MD 1.00, 95% CI 0.20 to 1.80).
Low dose compared to standard dose
There was evidence of fewer adverse effects, measured as lower TESS scores, in the low-dose group in the short term (2 RCTs, n = 266,
MD −3.99, 95% CI −5.75 to −2.24); and in one study there was evidence that the incidence of lethargy (RR 0.77, 95% CI 0.60 to
0.97), hypersalivation (RR 0.70, 95% CI 0.57 to 0.84), dizziness (RR 0.56, 95% CI 0.39 to 0.81) and tachycardia (RR 0.57, 95% CI
0.45 to 0.71) was less at low dose compared to standard dose.
Authors’ conclusions
We found no evidence of effect on mental state between standard, low and very low dose regimes, but we did not identify any trials
on high or very high doses of clozapine. BMI measurements were similar between groups in the short term, although weight gain was
less at very low dose compared to standard dose in one study. There was limited evidence that the incidence of some adverse effects
was greater at standard dose compared to lower dose regimes. We found very little useful data and the evidence available is generally
of low or very low quality. More studies are needed to validate our findings and report on outcomes such as relapse, remission, social
functioning, service utilisation, cost-effectiveness, satisfaction with care, and quality of life. There is a particular lack of medium- or
long-term outcome data, and on dose regimes above the standard rate.
P L A I N L A N G U A G E S U M M A R Y
Clozapine dose in schizophrenia
Background: Schizophrenia is a severe mental illness that affects thinking and perception. People with schizophrenia often experience
profound disruptions in their speech, emotional processes, behaviour and sense of self. Antipsychotic medication can be a helpful
treatment for schizophrenia; however, taking antipsychotic medication can have unpleasant effects. Clozapine is an antipsychotic drug
that can be useful in treating schizophrenia, particularly when other antipsychotic medications have not worked. It is unclear, however,
what dose of clozapine is most effective with the least side effects. This review investigates the effects of receiving clozapine at four
different dose levels (high dose, standard dose, low dose, very low dose).
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Searching: An electronic search for studies that randomised people with schizophrenia to receive different doses of clozapine was run in
August 2011 and again on 8 December 2016.
Results: We found five studies with 452 participants which met our inclusion criteria. Each compared the effects of clozapine at very
low dose (up to 149 mg/day), low dose (150 mg/day to 300 mg/day) and standard dose (301 mg/day to 600 mg/day). None of the
studies examined the effects of clozapine at higher than the standard dose. There was nothing to choose between standard, low and
very low doses in terms of body mass index (BMI) measurements in the short term. However, weight gain was greater in those receiving
the standard dose compared to those receiving the low dose. The incidence of unpleasant side effects (which included feeling lethargic,
producing too much saliva, and feeling dizzy) was less at low dose compared to standard dose.
Quality of evidence: For main outcomes the quality was low or very low.
Conclusions:We found no evidence that might indicate the best dose of clozapine for patients with schizophrenia. Careful consideration
has to be given to balancing the advantages and disadvantages of different doses in relation to weight gain and other side effects. Overall
measurements of BMI were similar between groups; however, some side effects appear to be lower at lower doses. Overall, this review
highlights the lack of evidence-based information available for addressing the question of what dose of clozapine is most effective with
the least side effects. There is a need for large, well-designed and well-reported randomised clinical trials to address this question. There
is a particular need for such trials to look at longer-term outcomes, and to examine the effects of clozapine when given at greater than
the standard dose.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
CLOZAPINE: VERY LOW DOSE (up to 149 mg/ day) versus LOW DOSE (150-300 mg/ day) for schizophrenia
Patient or population: pat ients with schizophrenia
Settings:
Intervention: Clozapine: very low dose (up to 149 mg/ day) versus low dose (150 mg/ day to 300 mg/ day)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Clozapine: very low
dose (up to 149 mg/
day) versus low dose
(150 mg/ day to 300
mg/ day)
Global state: clinically
important response, as
defined by individual
studies
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
M ental state: clinically
important response, as
defined by individual
studies *
Follow-up: 16 weeks
The mean clinical re-
sponse: mental state
- average scores -
medium term end-
point (BPRS-A, high =
worse) in the interven-
t ion group was
3.55 higher
(4.50 to 11.60 higher)
31
(1 study)
⊕©©©
very low1,2,3
* Pre-def ined outcome
not reported: Mental
state measured as av-
erage endpoint scores
(BPRS-A, high = worse)
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Functioning: clinically
important change in
general functioning, as
defined by individual
studies
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Adverse effect: clin-
ically important ad-
verse effect (weight -
BM I)
Follow-up: 6 weeks
The mean adverse ef -
fect - any clinically
important specif ic ad-
verse ef fects - BMI in
the intervent ion group
was
0.1 lower
(0.95 lower to 0.75
higher)
59
(1 study)
⊕⊕©©
low2,3
Service use: number of
days hospitalised
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Service use: time to
hospitalisation
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Quality of life: clini-
cally important change
in general quality of life
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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1 Risk of bias: rated as ’serious’ (downgraded by 1) due to attrit ion bias, report ing bias, and sponsorship by Novart is
Pharmaceut icals.
2 Indirectness: rated ’serious’ (downgraded by 1) as proxy measure of pre-def ined outcome
3 Imprecision: rated ’serious’ (downgraded by 1) as only one study providing data, small number of part icipants (less than
200)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Schizophrenia is a serious mental illness characterised by pro-
found disruptions in thinking and speech, emotional processes,
behaviour and sense of self (WHO 2013). It can have great impact
in terms of both human suffering and societal expenditure (van
Os 2009). It is among the world’s top ten causes of long-term dis-
ability, leading to problems in social and occupational functioning
and self-care (Meuser 2004). Before the introduction of clozapine,
doctors largely relied on first generation (typical) antipsychotics,
such as chlorpromazine, to control persisting symptoms and to
prevent further exacerbations or relapse of illness (Kane 1990).
Clozapine is the first second generation (atypical) antipsychotic
drug introduced to the market. Arnt suggested that second gen-
eration antipsychotics are those that do not cause movement dis-
orders (catalepsy) in rats at clinically effective doses (Arnt 1998).
When clozapine was introduced it proved to be superior in con-
trolling treatment-resistant illness, with fewer extrapyramidal side
effects (EPSEs) than typical antipsychotics such as chlorpromazine
(Kane 1988). However, clozapine was largely withdrawn from use
in 1975 following the death of some patients due to the develop-
ment of agranulocytosis. This withdrawal, however, was not fol-
lowed worldwide. For example, Scandinavia, Germany and China
continued to use clozapine. Subsequent studies demonstrated that
clozapine could be administered safely when patients are carefully
monitored for side effects such as agranulocytosis (Kane 1988;
Naheed 2001). Following this, clozapine was reintroduced in the
USA in 1990 with hopes that it would improve quality of life, cog-
nitive functioning and movement disorders, and also reduce nega-
tive symptoms such as poverty of speech, blunting of affect, lack of
volition and social withdrawal in themanagement of treatment-re-
sistant schizophrenia. During this reintroduction, some safeguards
were put in place; for example, clozapine is recommended to be
used only in treatment-resistant schizophrenia along with regular
monitoring for side effects such as agranulocytosis.
Description of the condition
1. Schizophrenia
WHO 2013 estimates that about 24 million people worldwide
are affected by schizophrenia. The symptoms typically emerge in
late adolescence or early adulthood. It is unclear as to what exactly
causes schizophrenia, but both genetic and environmental factors
are thought to play a role. WHO 2013 identified a low incidence
of 3 per 100,000, whereas McGrath 2008 identified the median
incidence of schizophrenia as 15.2 per 100,000 people. Saha 2005
found no significant difference in prevalence between urban, rural,
and mixed sites. The prevalence of schizophrenia in migrants is
higher compared to native-born individuals and is lower in poorer
countries than in richer countries. Saha 2005 identified the me-
dian point prevalence of schizophrenia (the proportion of people
who suffer from schizophrenia at a specific point in time) as 4.6
per 1000; the median lifetime prevalence for persons (the number
of people in the population who have ever manifested the disease)
was 4.0 per 1000; and the lifetime morbid risk (the likelihood of
a particular individual developing schizophrenia in their lifetime)
as 7.2 per 1000. Acute schizophrenia predominantly manifests it-
self with positive symptoms such as abnormal experiences; these
include abnormal perceptions in the absence of a stimulus (hal-
lucinations), false fixed beliefs (delusions), and disordered think-
ing. Chronic schizophrenia typically manifests itself with nega-
tive symptoms. Though there is no complete agreement as to the
specification of negative symptoms, it is generally agreed that they
include poverty of speech, blunting of affect, lack of volition and
social withdrawal (Gelder 2001). More than 50% of people with
schizophrenia are not receiving appropriate care and about 90% of
people with untreated schizophrenia live in developing countries
(WHO 2013). Most cases of schizophrenia can be treated and
those affected can lead a productive life and be integrated in soci-
ety. The incidence of treatment resistance in schizophrenia is about
20% (Kerwin 2005). Clozapine reduces psychotic symptoms in
30% to 60% of such schizophrenia patients who have failed to re-
spond to adequate trials of other antipsychotics (Buchanan 1995).
2. Schizophreniform disorder
According to theDiagnostic and Statistical Manual ofMental Dis-
orders, Fourth Edition, schizophreniform disorder is a condition
with symptoms similar to schizophrenia but lasting less than six
months (DSM-IV). In 1937 and 1939, follow-up studies were
undertaken on patients who initially presented with symptoms
similar to schizophrenia. Two different outcomes were identified
in those patients. One group, whose symptoms were typical of
schizophrenia, were identified as having a poor prognosis. The
other group, whose symptoms were similar to those of schizophre-
nia but who had prominent affective symptoms, had a better
outcome; Langfeldt introduced the concept of schizophreniform
psychoses to describe this latter group (Noreik 1967; Guldberg
1991). Langfeldt’s original schizophreniform cases were reviewed
by other researchers using DSM-III and International Statistical
Classification of Diseases and RelatedHealth Problems,Ninth Re-
vision (ICD-9) criteria. They concluded that most of the original
schizophreniform cases described by Langfeldt possibly appeared
to more closely resemble affective disorders with psychoses, rather
than schizophrenia-like illness (Bergem 1990; Guldberg 1991).
DSM-IV uses schizophreniform disorder to define a disorder that
would otherwise meet the diagnostic criteria for schizophrenia
but lasts less than six months (Gelder 2001). There are currently
no reliable data on prevalence rates of schizophreniform disorder
(Kaplan2005). Treatment is similar to that of schizophrenia.Good
prognostic factors for schizophreniform illness include episodic
illness, recurrent course and a family history of mood disorders
(Benazzi 2003).
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3. Schizoaffective disorder
In 1933 Jacob Kasanin coined the term schizoaffective psychosis
(Kasanin 1933). Schizoaffective psychosis can be considered as a
syndrome on the continuum between schizophrenia and mood
disorders (such as depression and bipolar affective disorder) and
presents with symptoms of both these illnesses (Danilevici te
2002). ICD-10 considers schizoaffective disorder as an episodic
disorder in which both affective and schizophrenic symptoms
are prominent but which does not justify a diagnosis of ei-
ther schizophrenia or a depressive or manic episode. Studies on
schizoaffective disorder suggest that it is relatively common in clin-
ical settings. Among admissions to inpatient mental health facil-
ities for functional psychosis, 10% to 30% comprise schizoaffec-
tive disorder. The lifetime prevalence of schizoaffective disorder is
estimated to be between 0.5% and 0.8% and the illness typically
presents with an episodic course (Azorin 2005). Psychotic features
may include both positive and negative symptoms along with af-
fective symptoms. Outcome is predicted by premorbid function-
ing, number of past episodes, persistence of psychotic features and
degree of cognitive impairment. Vieta 2010 suggests that bipo-
lar-type schizoaffective illness can be treated with second genera-
tion antipsychotics, either alone or in conjunction with a mood
stabiliser. The depressive type of schizoaffective disorder can be
treatedwith a second generation antipsychotic in conjunctionwith
either an antidepressant or a mood stabiliser. Electroconvulsive
therapy (ECT) can be considered in refractory cases. Prognosis
appears to be better than for schizophrenia, but worse than for
affective disorder (Azorin 2005).
Description of the intervention
Prescribing of clozapine requires a number of preparatory steps.
For example, before initiation of clozapine a base line physical ex-
amination should be performed with an ECG and base line blood
tests, including full blood count. Patients must be registered with
the clozapine patient monitoring services, and full blood count
must be monitored once a week for the first 18 weeks, thereafter
fortnightly for 34 weeks and then once in every four weeks for
the period of time clozapine is taken. For adults over 16 years
of age, clozapine should be started at a very low dose, e.g. 12.5
mg once or twice a day. On the second day, 25 mg to 50 mg is
given, and, if well tolerated, the dose can be gradually increased
in steps of 25 mg to 50 mg daily over 14 to 21 days up to 300
mg daily in divided doses. If necessary, the dose can be increased
further. Elderly people may need slower titration. During initia-
tion and titration, pulse and blood pressure (in standing and ly-
ing position) should be monitored regularly to identify persistent
tachycardia and postural hypotension. If clozapine, for whatever
reason, was omitted for a period of 48 hours, it should be restarted
from lowest dose and titrated upwards. Adverse effects of clozap-
ine include constipation, troublesome hypersalivation, tachycar-
dia, ECG changes, hypertension, drowsiness, dizziness, headache,
tremor, seizures, fatigue, impaired temperature regulation, urinary
incontinence, urinary retention, leukopenia, eosinophilia, leuco-
cytosis, and, less commonly, agranulocytosis, and other cardiovas-
cular and respiratory side effects (BNF 2012).
Accessibility of clozapine
Upon reintroduction of clozapine in the USA in 1990, cloza-
pine was recommended to be used only in treatment-resistant
schizophrenia, along with regular monitoring for side effects such
as agranulocytosis. The British National Formulary currently rec-
ommends clozapine be used only in “schizophrenia (including psy-
chosis in Parkinson’s disease) in patients unresponsive to, or in-
tolerant of, conventional antipsychotic drugs” (BNF 2012). The
National Institute for Health and Care Excellence recommends
clozapine in people suffering from schizophrenia who did not re-
spond adequately to sequential use of adequate doses of at least
two different antipsychotic drugs, at least one of which should be
a non-clozapine second-generation antipsychotic (NICE). Cloza-
pine is made available only through the manufacturer’s propri-
etary monitoring system, and all the UK manufacturers of clozap-
ine such as Novartis (Clozaril), Merz (Denzapine), and Teva (Za-
ponex) require that the patients, prescribers and supplying phar-
macists be registered with their relevant patient monitoring ser-
vice. Through shared care arrangements with local community
pharmacies dispensing clozapine, it is possible in theUK to initiate
clozapine treatment in the community after registration with the
patient monitoring services is completed (CMHP).However, gen-
eral practitioners generally do not prescribe clozapine in the UK.
Aitchison 1997 suggested that the costs of prescribing clozapine
could be recouped on savings in future inpatient care. Wang 2004
indicated that if clozapine was made available as a first-line an-
tipsychotic, it might possibly lead to small gains in life expectancy,
atmoderate but acceptable costs. Kane 2011 opined that clozapine
still remains strikingly under-utilised and that many practitioners
across the world and across different clinical settings do not use
clozapine even when indicated.
How the intervention might work
Clozapine (Figure 1) was the first atypical antipsychotic to show
definite benefit in treatment of patients where symptoms failed to
respond to typical agents. Clozapine has the highest affinity for
dopamine D4, 5-HT1C, 5-HT2, alpha 1, muscarinic and his-
tamine H1 receptors, but moderate affinity is also seen for many
other receptor subtypes (Coward 1992). Clozapine causes fewer
extrapyramidal side effects (EPSEs) than typical antipsychotics
(Kane 1988). Clozapine appears to bemore active at the limbic site
than the striatal site and this might explain its low extrapyramidal
side effect profile. It is metabolized mainly in the liver. Norcloza-
pine is an active metabolite of clozapine. Monitoring the plasma
levels of clozapine and norclozapine helps to assess compliance. It
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is suggested that the therapeutic response is associated with clozap-
ine blood levels between 200 ng/ml and 400 ng/ml (Kronig 1995).
Chemicals that affect cytochrome enzymes can reduce or increase
plasma clozapine concentration.
Figure 1. Clozapine structure
Why it is important to do this review
Different guidelines suggest different dosing for clozapine. For ex-
ample, BNF 2012 recommends a usual dose of 200 mg/day to
450 mg/day and the maximum daily dose of 900 mg. Merz, the
UK manufacturer of Denzapine, also advises the prescription of
clozapine at a dose between 200 mg/day and 450 mg/day, with
maximum doses up to 900 mg/day. Novartis, the UK manufac-
turer of Clozaril, suggests that while many patients may respond
adequately at doses between 300 mg/day and 600 mg/day, it may
be necessary to raise the dose to the 600 mg/day to 900 mg/day
range to obtain an acceptable response. Kaplan 2005 suggests that
daily doses between 250 mg/day and 450 mg/day are usually con-
sidered adequate and daily dosage above 600 mg/day is seldom
indicated. Semple 2007 advises that usual doses of 200 mg to 450
mg daily can be used, and that an increase in frequency of seizures
occurs at doses greater than 600 mg/day. Stahl 2006 suggests us-
ing 300 mg/day to 450 mg/day with a maximum of 900 mg/day,
and that doses of more than 550 mg/day may require concomitant
anticonvulsant medications to reduce the risk of seizures. Plasma
levelsmay help guide dosing, with studies suggesting that maximal
clinical efficacy may be achieved when plasma levels of clozapine
are between 200 ng/ml and 400 ng/ml (typically associated with a
dose of 300mg/day to 400mg/day (Kronig 1995; Simpson 1999).
However, it is important to note that the relationship between the
dose of clozapine and the resulting serum level is weak (Taylor
1995). This could be a reason why there is wide variation of the
clinically effective dose in different individuals. It is still unclear as
towhat dose of clozapine ismost effectivewith the least side effects.
It must be borne in mind as well that patient non-compliance can
be as high as 50% under outpatient conditions and this could be
due to drug-related side effects (Gaebel 1997), and lead to relapse.
Clozapine produces severe adverse effects. Hence we will review
the evidence for doses of clozapine that are both tolerable and
effective in the management of schizophrenia, schizophreniform
and schizoaffective disorders. This is one of a series of reviews on
the effects of clozapine (Table 1).
O B J E C T I V E S
To compare the efficacy and tolerability of clozapine at different
doses and to identify the optimal dose of clozapine in the treatment
of schizophrenia, schizophreniform and schizoaffective disorders.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We included all relevant randomised controlled trials, reporting
useable data, that compared different doses of clozapine, irrespec-
tive of blinding status and published language. Where people were
given additional treatments along with clozapine, we included the
trial only if the adjunct treatment was equal in both groups and
only the clozapine doses were randomised. We included studies on
treatment-resistant illnesses and took the opportunity to examine
clozapine’s effect on the course of the illness (for example acute,
partial remission, remission, first episode).We excluded case series
and non-randomised trials, and quasi-randomised trials where, for
example, allocation is undertaken on alternate days of the week or
by alphabetical order.
Types of participants
We included studies on people with schizophrenia, schizophreni-
form disorder and schizoaffective disorder diagnosed by any crite-
ria. We decided to include schizophreniform and schizoaffective
disorders as these conditions may be caused by similar disease pro-
cesses and may require similar treatment approaches (Carpenter
1994).
Types of interventions
We compared the efficacy of different doses of clozapine in differ-
ent arms in the same trial. We did not compare efficacy of clozap-
ine to any other antipsychotic or to placebo or to any other medi-
cations. The intervention of interest was clozapine: oral formula-
tion, any dose, comparison of different doses. We predefined the
dosage categories as follows.
1. Very low dose clozapine: up to 149 mg/day.
2. Low-dose clozapine: 150 mg/day to 300 mg/day.
3. Standard-dose clozapine: 301 mg/day to 600 mg/day.
4. High-dose clozapine: 601 mg/day to 900 mg/day.
5. Very high dose clozapine: 901 mg/day and above.
Types of outcome measures
We grouped outcomes into short term (up to 12 weeks), medium
term (13 to 26 weeks) and long term (more than 26 weeks).
Primary outcomes
1. Global state
Clinically important response as defined by the individual studies
(e.g. global impression “much improved” or 50% reduction on a
rating scale).
Secondary outcomes
1. Global state
1.1 Relapse (as defined by the individual studies).
1.2 Average endpoint global state score.
1.3 Average change in global state scores.
1.4 Needing additional medication.
2. Mental state
2.1 Clinically important change in general mental state score.
2.2 Average endpoint general mental state score.
2.3 Average change in general mental state scores.
2.4Clinically important change in specific symptoms (e.g. positive
symptoms of schizophrenia, negative symptoms of schizophrenia).
2.5 Average endpoint specific symptom score.
2.6 Average change in specific symptom scores.
2.7 Healthy days.
3. Death
3.1 Suicide.
3.2 Natural causes.
4. Leaving the studies early
4.1 Any reason.
4.2 Specific reason (as described by individual studies; for example:
adverse events, treatment inefficacy).
5. Behaviour
5.1 Clinically important change in general behaviour.
5.2 Average endpoint general behaviour score.
5.3 Average change in general behaviour scores.
5.4 Clinically important change in specific aspects of behaviour.
5.5 Average endpoint specific aspects of behaviour.
5.6 Average change in specific aspects of behaviour.
6. Functioning
6.1 Clinically important change in general functioning.
6.2 Average endpoint general functioning score.
6.3 Average change in general functioning scores.
6.4 No clinically important change in specific aspects of function-
ing, such as social or life skills.
6.5 Average endpoint specific aspects of functioning, such as social
or life skills.
6.6 Average change in specific aspects of functioning, such as social
or life skills.
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7. Cognitive functioning
7.1 Clinically important change in overall cognitive functioning.
7.2 Average endpoint overall cognitive functioning score.
7.3 Average change in overall cognitive functioning score.
7.4 Clinically important change in specific aspects of cognitive
functioning.
7.5 Average endpoint specific aspects of cognitive functioning.
7.6 Average change in specific aspects of cognitive functioning.
8. Quality of life
8.1 Clinically important change in general quality of life.
8.2 Average endpoint general quality of life score.
8.3 Average change in general quality of life score.
8.4 Clinically important change in specific aspects of quality of
life.
8.5 Average endpoint specific aspects of quality of life.
8.6 Average change in specific aspects of quality of life.
9. Adverse effects
9.1 Number of participants with at least one adverse effect.
9.2 Clinically important specific adverse effects (such as effects
on white blood cell count, cardiac effects, movement disorders,
hypersalivation, seizures, prolactin increase and metabolic side ef-
fects (such as weight gain, hyperlipidaemia and hyperglycaemia)).
9.3 Clinically important general adverse effects.
9.4 Average endpoint general adverse effect score.
9.5 Average change in general adverse effect score.
9.6 Average endpoint specific adverse effect score.
9.7 Average change in specific adverse effect score.
9.8 Use of any drugs for adverse effects.
10. Satisfaction with treatment
10.1 Recipient of care not satisfied with treatment.
10.2 Recipient of care average satisfaction score.
10.3 Recipient of care average change in satisfaction score.
10.4 Carer not satisfied with treatment.
10.5 Carer average satisfaction score.
10.6 Carer average change in satisfaction score.
11. Service use
11.1 Number of patients hospitalised.
11.2 Number of days hospitalised.
11.3 Time to hospitalisation.
11.4 Number of patients discharged or readmitted (as defined in
individual trial).
12. Economic outcomes
12.1 Direct costs.
12.2 Indirect costs.
13. ’Summary of findings’ table
Weused theGRADEapproach to interpret findings (Schünemann
2011); and GRADE Profiler (GRADEpro GDT) to import data
from Review Manager 5 (RevMan 5) to create ’Summary of find-
ings’ tables. These tables provide outcome-specific information
concerning the overall quality of evidence from each included
study in the comparison, the magnitude of effect of the inter-
ventions examined and the sum of available data on all outcomes
we rated as important to patient care and decision making. We
selected the following outcomes for inclusion in the Summary
of findings for the main comparison; Summary of findings 2;
Summary of findings 3.
1. Global state: clinically important response, as defined by
individual studies.
2. Mental state: clinically important response, as defined by
individual studies.
3. Functioning: clinically important change in general
functioning, including social or life skills, as defined by
individual studies.
4. Adverse effect: clinically important adverse effect.
5. Service use: number of days hospitalised.
6. Service use: time to hospitalisation.
7. Quality of life: clinically important change in general
quality of life.
Search methods for identification of studies
Electronic searches
Cochrane Schizophrenia Group’s Study-Based Register of
Trials
On 8 December 2016, the information specialist searched the
register using the following search strategy:
Dosage - Clozapine in Intervention Field of STUDY
In a study-based register such as this, searching the major con-
cept retrieves all the synonyms and relevant studies because all the
studies have already been organised based on their interventions
and linked to the relevant topics.
This register is compiled by systematic searches of major re-
sources (including AMED, BIOSIS, CINAHL, Embase, MED-
LINE, PsycINFO, PubMed, and registries of clinical trials) and
their monthly updates, handsearches, grey literature, and confer-
ence proceedings (see Group’s Module). There is no language,
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date, document type, or publication status limitations for inclu-
sion of records in the register.
For previous searches, please see Appendix 1.
Searching other resources
1. Reference searching
We searched the reference lists of each included paper, but failed
to find any new studies.
2. Personal contact
Where possible, we contacted the first author of trials or citations
for missing information on unpublished data or trials.Where con-
tact with the first author was not possible through the Cochrane
Schizophrenia Group, we attempted to contact the other authors.
At the time of writing, we have not received any of the missing
data we requested, though one author indicated he will send the
requested information at a future date. We have discussed this in
detail under relevant Results sections.
Data collection and analysis
Selection of studies
One review author (SS) inspected citations from the searches,
identified relevant abstracts, obtained full articles of all relevant
abstracts, and classified studies as ’included’, ’excluded’, or ’with
information missing’. We placed the last under ’pending classifica-
tion’ and contacted the authors for further clarification. A second
review author (BV) independently inspected a random 20% of
citations to ensure reliability.
Data extraction and management
1.1 Data extraction
One review author (SS) extracted data from all included reports.
To ensure reliability, a second review author (BV) independently
extracted data from a random 25% sample of these reports. There
was nodisagreement.Had there beendisagreement, wewould have
documented decisions and contacted authors of studies for clarifi-
cation where necessary. We extracted data presented in graphs and
figures only, whenever possible. We attempted to contact authors
in order to obtain missing information or clarification whenever
necessary.
1.2 Forms
We extracted data onto standard forms.
2. Data management
2.1 Scale-derived data
We included continuous data from rating scales only if (a) the
psychometric properties of the measuring instrument had been
described in a peer-reviewed journal (Marshall 2000), and (b)
the measuring instrument had not been written or modified by
one of the trialists for that particular trial. Ideally the measuring
instrument should either be:
(a) a self-report;
(b) an instrument completed by an independent rater or relative
(not the therapist);
(c) a global assessment of an area of functioning and not sub-
scores which are not, in themselves, validated or shown to be reli-
able. However there are exceptions: we included sub-scores from
mental state scales measuring positive and negative symptoms of
schizophrenia.
We realise that this is not often reported clearly and we note in
Description of studies if this was the case or not.
2.2 Endpoint versus change data
There are advantages of both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis. On the other hand, calculation of change needs two
assessments (baseline and endpoint) which can be difficult in un-
stable and difficult-to-measure conditions such as schizophrenia.
We primarily used endpoint data, and only used change data if
the former were not available. We combined endpoint and change
data in the analysis by the use throughout of mean differences
(MD) rather than standardised mean differences (Deeks 2011).
2.3 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying paramet-
ric tests to non-parametric data, we aimed to apply the following
standards to all data before inclusion: a) standard deviations and
means are reported in the paper or obtainable from the authors;
b) when a scale starts from the finite number zero, the standard
deviation, when multiplied by two, is less than the mean (as oth-
erwise the mean is unlikely to be an appropriate measure of the
centre of the distribution (Altman 1996); c) if a scale started from
a positive value (such as the PANSS which can have values from
30 to 210), the calculation described above was modified to take
the scale starting point into account. In these cases skew is present
if 2SD > (S −S min), where S is the mean score and S min is
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the minimum score. Endpoint scores on scales often have a finite
start and end point and the above rules can be applied. We did
not come across skewed endpoint data in our review, but if we had
then we would have entered skewed endpoint data from studies
of fewer than 200 participants as other data within the Data and
analyses section rather than into a statistical analysis. Skewed end-
point data would pose fewer problems when looking at means if
the sample size is large, and we would have then entered these into
syntheses.
When continuous data are presented on a scale that includes a
possibility of negative values (such as change data), it is difficult
to tell whether data are skewed or not, and we would have entered
skewed change data into statistical analysis.
2.4 Common measure
To facilitate comparison between trials, where possible we tried
to convert variables reported in different metrics (e.g. days spent
in hospital as mean days per year or per week or per month) to a
common metric (e.g. mean days per month).
2.5 Conversion of continuous to binary
Where possible, we would have converted outcome measures to
dichotomous data. This would have been done by identifying cut-
off points on rating scales and dividing participants accordingly
into ’clinically improved’ or ’not clinically improved’. It is generally
assumed that if there is a 50% reduction in a scale-derived score
such as the Brief Psychiatric Rating Scale (BPRS, Overall 1962)
or the Positive and Negative Syndrome Scale (PANSS, Kay 1986),
this could be considered as a clinically significant response (Leucht
2005a; Leucht 2005b). If data based on these thresholds had not
been available, we would have used the primary cut-off presented
by the original authors. Where data on clinical improvement was
presented as ’very effective’, ’effective’ and ’no improvement’, we
grouped these to form the dichotomous outcome of ’effective’/’no
improvement’.
2.6 Direction of graphs
Where possible, we entered data in such a way that the area to
the left of the line of no effect indicates a favourable outcome for
lower dose of clozapine.
Assessment of risk of bias in included studies
One review author (SS) independently assessed risk of bias by using
criteria described in the Cochrane Handbook for Systematic Reviews
of Interventions to assess trial quality (Higgins 2011b). A second
review author (BV) randomly checked 25% to ensure reliability.
This set of criteria is based on evidence of associations between
overestimate of effect and high risk of bias of the article such as se-
quence generation, allocation concealment, blinding, incomplete
outcome data and selective reporting. There was no disagreement.
If there had been disagreement, we would have resolved it by fur-
ther discussion. The level of risk of bias is noted in both the text
of the review and in the ’Summary of findings’ table.
Measures of treatment effect
1. Binary data
For binary outcomes we calculated a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI). It has been
shown that RR is more intuitive than odds ratios (Boissel 1999);
and that odds ratios tend to be interpreted as RR by clinicians
(Deeks 2000). The number needed to treat for an additional ben-
eficial outcome/harmful outcome (NNTB/NNTH) statistic with
its confidence intervals is intuitively attractive to clinicians but is
problematic both in its accurate calculation in meta-analyses and
interpretation (Hutton 2009). For binary data presented in the
’Summary of findings’ table/s, where possible we calculated illus-
trative comparative risks.
2. Continuous data
We estimated mean difference (MD) between groups for contin-
uous outcomes. We preferred not to calculate effect size measures
(standardised mean difference (SMD)). However, if very similar
scales had been used, we would have presumed there was a small
difference in measurement and would have calculated effect size
and transformed the effect back to the units of one or more of the
specific instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data poses problems. Firstly, authors often fail to account
for intra-class correlation in clustered studies, leading to a ’unit
of analysis’ error (Divine 1992), whereby P values are spuriously
low, confidence intervals unduly narrow and statistical significance
overestimated. This causes type I errors (Bland 1997; Gulliford
1999).
There were no cluster trials included in our review. If there had
been cluster studies, then where clustering was not accounted for
in primary studies we would have presented data in a table, with a
(*) symbol to indicate the presence of a probable unit of analysis
error. In subsequent versions of this review we will contact first
authors of studies to obtain intra-class correlation coefficients for
their clustered data and adjust for this by using accepted methods
(Gulliford 1999).
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If clustering had been incorporated into the analysis of primary
studies, we would have presented these data as if from a non-clus-
ter randomised study, but would have adjusted for the clustering
effect. Statistical advice has been sought in the past: it was advised
that binary data should be presented in a report and divided by a
’design effect’. This is calculated using the mean number of par-
ticipants per cluster (m) and the intra-class correlation coefficient
(ICC): [Design effect = 1 + (m − 1) * ICC] (Donner 2002). If
the ICC had not been reported we would have assumed it to be
0.1 (Ukoumunne 1999). If cluster studies had been appropriately
analysed taking into account intra-class correlation coefficients
and relevant data documented in the report, synthesis with other
studies might have been possible using the generic inverse variance
technique.
2. Cross-over trials
We only used data from the first phase of cross-over studies. A
major concern of cross-over trials is the carry-over effect. It occurs
if an effect (e.g. pharmacological, physiological or psychological)
of the treatment in the first phase is carried over to the second
phase. As a consequence, on entry to the second phase participants
can differ systematically from their initial state despite a wash-out
phase. For the same reason cross-over trials are not appropriate
if the condition of interest is unstable (Elbourne 2002). Because
both these effects are very likely in severemental illness, we decided
to use data from the first phase of cross-over studies only. In our
review, the Simpson 1999 trial was conducted in three phases of
16 weeks each, lasting for a total of 48 weeks with the last two
phases being crossed over. For this trial we included the data from
the first 16 weeks only (i.e. before cross-over occurred).
3. Studies with multiple treatment groups
There was no relevant additional treatment in any of the included
trials. If a study had involved additional treatment arms, we would
have presented the additional arms in comparisons only if rele-
vant and would not have reproduced data from irrelevant arms.
For binary data, we would simply have added these and combined
within a two-by-two table. For continuous data, we would have
combined the data following the formula in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011a). In
cases where a study had two intervention arms which both fell
within a single-dosage category defined in Types of interventions
(for example, in Chen 2013 where both the 301 mg/day to 400
mg/day intervention and the 401 mg/day to 500mg/day interven-
tion fell within the ‘standard’ dose category), means and standard
deviations were combined for continuous outcomes using meth-
ods described in section 7.7.3.8 of Higgins 2011a.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). If more than 50% of data had been unaccounted for in any
particular outcome, we had decided neither to reproduce these
data nor to use them within our analyses. In this review, however,
loss of data was never more than 50% for any outcome or in any
arm. If the loss of data had been more than 50% but the total loss
had been less than 50%, we would have marked such data with
(*) to indicate that the result might have been prone to bias.
2. Binary
Those who left the study early were all assumed to have the same
outcome as those who completed, with the exception of the out-
comes of death and adverse effects.
3. Continuous
3.1 Attrition
Had attrition for a continuous outcome been between 0% and
50% and completer-only data had been reported, we would have
reproduced these data.
3.2 Standard deviations
In our review, there were few data whose standard deviations (SDs)
were missing. We tried to obtain the missing values from the au-
thors, but were unsuccessful. Where there are missing measures of
variance for continuous data, but an exact standard error (SE) and
confidence intervals available for group means, and either P value
or t value available for differences in mean, we can calculate them
according to the rules described in the Cochrane Handbook for Sys-
tematic reviews of Interventions (Higgins 2011a): When only the
standard error (SE) is reported, SDs are calculated by the formula
SD = SE * square root (n). The Cochrane Handbook for Systematic
reviews of Interventions (Higgins 2011a) present detailed formulae
for estimating SDs from P values, t or F values, confidence in-
tervals, ranges or other statistics. If these formulae do not apply,
we could calculate the SDs according to a validated imputation
method which is based on the SDs of the other included studies
(Furukawa 2006). Although some of these imputation strategies
can introduce error, the alternative would be to exclude a given
study’s outcome and thus to lose information. We examined the
validity of the imputations in a sensitivity analysis excluding im-
puted values. In our review we needed to exclude some outcome
data as suggested by this last option.
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3.3 Last observation carried forward
We anticipated that in some studies the method of last observa-
tion carried forward (LOCF) would have been reported. As with
all methods of imputation to deal with missing data, LOCF in-
troduces uncertainty about the reliability of the results (Leucht
2007). We found no cases where less than 50% of the LOCF data
were available; if we had, we would have reproduced these data
and indicated that they were based on LOCF assumptions.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing com-
parison data to judge clinical heterogeneity.We inspected all stud-
ies for clearly outlying people or situations which we had not pre-
dicted would arise, but we did not come across any such outlying
conditions.
2. Methodological heterogeneity
We considered all included studies initially without seeing com-
parison data to judge methodological heterogeneity. We simply
inspected all studies for clearly outlying methods which we had
not predicted would arise, but we did not come across any such
outlying methods.
3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected the graphs to investigate the possibility of
statistical heterogeneity.
3.2 Employing the I² statistic
We investigated heterogeneity between studies by considering the
I² method alongside the Chi² P value. The I² provides an estimate
of the percentage of inconsistency thought to be due to chance
(Higgins 2003). The importance of the observed value of I² de-
pends on (i) magnitude and direction of effects, and (ii) strength
of evidence for heterogeneity (e.g. P value from Chi² test, or a
confidence interval for I²). I² estimates greater than or equal to
50% and accompanied by a statistically significant Chi² statistic
are interpreted as evidence of substantial levels of heterogeneity
(Deeks 2011). If substantial levels of heterogeneity had been found
in the primary outcome, we would have explored reasons for het-
erogeneity (Subgroup analysis and investigation of heterogeneity).
Assessment of reporting biases
1. Protocol versus full study
We attempted to locate protocols of the included randomised tri-
als but were unsuccessful. We therefore compared the outcomes
listed in theMethods section of the trial report with those actually
reported in the results.
2. Funnel plot
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Chapter 10 of the Cochrane Handbook for
Systematic Reviews of Interventions (Sterne 2011). We are aware
that funnel plots may be useful in investigating reporting biases
but have limited power to detect small-study effects. We did not
use funnel plots as there were only three randomised controlled
studies included in this review.
Data synthesis
We understand that there is no closed argument in favour of ei-
ther a fixed-effect or a random-effects model. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model: it adds weight to small studies, which often
are the most biased ones. Depending on the direction of effect,
these studies can either inflate or deflate the effect size. We chose
a random-effects model for all analyses. The reader is, however,
able to choose to inspect the data using the fixed-effect model by
opening this review in RevMan 5 format and selecting to view by
“fixed effect” model under the properties section of each graph.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
We had planned to report data on subgroups of participants (for
example, those who received additional medications or had addi-
tional diagnoses), but we did not encounter such subgroups.
1.1 Clinical state, stage or problem
This review provides an overview of the effects of clozapine for
people with schizophrenia, schizophreniform and schizoaffective
disorder. Our aim was also to report data on subgroups of people
in the same clinical state, stage and with similar problems (for
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example patients in agitated state, partial remission, remission or
first episode), but we did not come across any such subgroups.
2. Investigation of heterogeneity
We report if inconsistency was high. First, we investigated whether
data were entered correctly. Secondly, if the data were correct, we
visually inspected the graphs and successively removed outlying
studies to see if heterogeneity was restored. For this review we
decided that we would present the data if this occurred in no
more than 10% of the total weighting of the summary findings. If
not, we would not pool data but would only discuss the issues. If
unanticipated clinical or methodological heterogeneity had been
obvious, we would have stated the hypotheses regarding these for
future reviews or versions of this review and would not have un-
dertaken analyses relating to these.
Sensitivity analysis
1. Implication of randomisation
Wewould have included in a sensitivity analysis primary outcomes
data from studies where randomisation was implied but was not
clearly described, but we did not come across such studies. If there
had been no substantive difference when the implied randomised
studies were added to those with better description of randomisa-
tion, then we would have employed all data from these studies.
2. Assumptions for lost binary data
Where assumptions were made regarding participants lost to fol-
low-up (see Dealing with missing data) we would have compared
the findings of the primary outcomes when we used our assump-
tion compared with completer data only. If there had been a sub-
stantial difference, we would have reported the results and dis-
cussed thembutwould have continued to employ our assumption.
Where assumptions were made regarding missing SDs data (see
Dealing with missing data), we would have compared the findings
on primary outcomes when we used our assumption compared
with completer data only. We would have undertaken a sensitivity
analysis testing as to how prone results would have been to change
with completer data only compared to the imputed data using the
above assumption. If there would have been a substantial differ-
ence, we would have reported these results and discussed them
but would have continued to employ our assumption. We did not
have to make such assumptions in our review.
3. Risk of bias
We analysed the effects of excluding trials that were judged to be
at high risk of bias across one or more of the domains - randomi-
sation, allocation concealment, blinding and outcome reporting
and other bias - for the meta-analyses of the primary outcome. If
the exclusion of trials at high risk of bias did not substantially alter
the direction of effect or the precision of the effect estimates, then
we included data from these trials in the analysis.
4. Imputed values
We did not include any cluster trials. If any had been included, we
would have undertaken sensitivity analysis to assess the effects of
including data from trials where we had used imputed values for
ICCs in calculating the design effect. If substantial differences in
the direction or precision of effect estimates in any of the sensitivity
analyses had been noted, we would not have pooled data, but
would have presented them separately.
5. Fixed-effect and random-effects
We synthesised all data using a random-effects model.
R E S U L T S
Description of studies
For substantive descriptionof studies please also seeCharacteristics
of included studies, Characteristics of excluded studies and Char-
acteristics of ongoing studies.
Results of the search
The search strategy yielded 122 citations. One was a duplicate.
We closely inspected 23 full-text reports; and after excluding 18
full-text reports, we included five studies in the review. A random
20% of the citations were independently reviewed by one review
author (BV) to increase reliability. Details of the search results are
illustrated in the PRISMA table (Figure 2).
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Figure 2. Study flow diagram.
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Included studies
We included five studies with a total of 452 participants.
1. Study length
Chen1998 andChen 2013were short-term trials lasting sixweeks.
Sheng 1990 and Liu 2005 were also short term (12 weeks). The
Simpson 1999 trial was originally conducted in three phases of
16 weeks each, lasting for a total of 48 weeks. However, after the
first 16 weeks, the non-responders in the trial were crossed over
to other arms and hence they were not randomised anymore after
the initial 16 weeks. So, as per protocol, we included the results
of only the first 16 weeks (medium term: 13 to 26 weeks) from
these citations. There were no long-term studies (> 26 weeks).
2. Design
All included studies were randomised controlled trials. Chen 1998
is a randomised controlled trial comparing the efficacy of cloza-
pine at doses of 200 mg and 500 mg; details of blinding status
and of any sponsorship are unclear. Liu 2005 is a randomised con-
trolled trial comparing clozapine at doses of less than 150 mg/day,
150 mg/day to 300 mg/day and more than 300 mg/day, in which
participants were allocated using a random number table; details
of blinding status and of any sponsorship are unclear. Chen 2013
is a randomised trial comparing doses of 200 mg/day to 300 mg/
day, 301 mg/day to 400 mg/day and 401 mg/day to 500 mg/day.
Sheng 1990 is a randomised trial comparing doses of 300 mg/day
and 600 mg/day. Simpson 1999 is an implied randomised con-
trolled trial comparing the efficacy of clozapine at different doses
of 100 mg/day, 300 mg/day and 600 mg/day in 50 patients. The
trial was sponsored by Novartis Pharmaceuticals and conducted
between 1992 and 1995; the participants stayed in the research
centre for four weeks for adaptation (naturalistic baseline with no
modification in their treatment regimen) and underwent a four-
week haloperidol treatment followed by a one-week wash out be-
fore the first phase of clozapine treatment.
3. Participants
A total of 452 participants were included in the five trials. Chen
1998 conducted their study on a total of 176 male and female pa-
tients, aged between 17 and 55 years, suffering from schizophre-
nia and with illness duration of 8 (± 11 months) on average. Liu
2005 included 87 male patients aged between 18 and 45 years and
used CCMD-3 to diagnose patients suffering from schizophre-
nia. Chen 2013 and Sheng 1990 randomised 90 and 51 patients
with schizophrenia, respectively. Simpson 1999 was conducted on
a total of 22 males and 28 females with a mean age of 44.8 years
(range 35 to 54) suffering from schizophrenia, treatment refrac-
tory or schizoaffective disorder, diagnosed by DSM-III-R criteria.
Mean illness duration was 25.1 years (range 1 to 38 years) and the
median number of psychiatric hospitalisations was five (range 1
to 25). Patients had not shown a satisfactory clinical response to
treatment with at least three neuroleptic drugs (each given for at
least six weeks in doses equivalent to 1000 mg/day of chlorpro-
mazine).
4. Settings
Simpson 1999 used a research ward inpatient setting in a State
hospital in the USA. Liu 2005 was conducted in an inpatient
setting in a medical college. The settings for Chen 1998, Chen
2013 and Sheng 1990 were unclear.
5. Interventions
We classified interventions into five groups according to clozapine
dosage. Liu 2005 administered clozapine at less than 150 mg/day
(very low dose), at 150 mg/day to 300 mg/day (low dose) and at
more than 300 mg/day (standard dose). Simpson 1999 adminis-
tered clozapine at 100 mg/day (very low dose), 300 mg/day (low
dose) and 600 mg/day (standard dose). Chen 1998 administered
clozapine at 200 mg/day (low dose) and at 500 mg/day (standard
dose). Chen 2013 administered doses of 200 mg/day to 300 mg/
day, 301 mg/day to 400 mg/day and 401 mg/day to 500 mg/day.
Sheng 1990 administered doses of 300 mg/day and 600 mg/day.
No trial administered clozapine at more than 601 mg/day (high
dose) or more than 901 mg/day (very high dose).
6. Outcomes
6.1 Rating scales
Details of the scales that provided usable data are shown below.
Reasons for exclusions of data and/or scales are given under ‘Out-
comes’ in the Characteristics of included studies table.
6.1.1 Mental state
6.1.1.1 Brief Psychiatric Rating Scale BPRS (Overall 1962)
The BPRS is an 18-item scale measuring positive symptoms, gen-
eral psychopathology and affective symptoms. High scores indi-
cate more severe symptoms. The original scale has 16 items that
are rated in interview format using Likert scale ratings from 1
(‘absent’) to 7 (‘very severe’) with scores ranging from 0 to 112. A
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revised 18-item scale is commonly used with scores ranging from
0 to 126. The BPRS-A is an anchored version of the BPRS. It
describes expected symptoms and problems for each of the seven
rating options for each item. As such, it is thought that the BPRS-
A anchor points provide an increased level of standardisation, lead-
ing to an improvement in rater reliability (Woerner 1988). The
BPRS-A and its subscales have been validated (Lachar 2001).Chen
1998 and Simpson 1999 reported data on the BPRS-A.
6.1.2 Adverse events
6.1.2.1 Treatment-Emergent Signs and Symptoms - TESS (
NIMH 1985)
This checklist assesses a variety of characteristics for each adverse
event, including severity, relationship to the drug, temporal char-
acteristics (timing after a dose, duration and pattern during the
day), contributing factors, course, and action taken to counteract
the effect. Symptoms can be listed a priori or can be recorded as
observed by the investigator. A low score indicates low levels of
adverse effects. Chen 1998 and Chen 2013 reported data on this
outcome.
Excluded studies
Of the 122 references identified using the search strategy, one was
a duplicate. We closely inspected 28 reports and excluded 23. Liu
2005a and Tang 2000 were not randomised trials. All data were
missing in de Leon 1995a and de Leon 2004 and we contacted the
author who confirmed that no further data were available. de Leon
2003 was excluded as the data on serum antimuscarinic activity
was missing at 16 weeks before the cross-over point. Potkin 1993
and Potkin 1994 also had all data missing from the reports and no
data were useable; we contacted the author regarding the missing
data but no response has been received at the time of writing. We
excluded Han 2001 as different doses of sulpiride were prescribed
in the clozapine arms. VanderZwaag 1996 andVanderZwaag 1997
compared the effectiveness of different serum clozapine levels, but
not the effects of different doses of clozapine. Nair 1998 and
Nair 1999 were excluded because the authors compared those
with and without probable tardive dyskinesia in subgroups of 23
and 33 participants respectively from the Simpson 1999 trial, but
provided no additional data relevant to this review.
Studies awaiting classification
Abraham 1997 is a report of a trial conducted from 1992 to 1995,
reported in detail in Simpson 1999 where it is mentioned that
global state was measured using the Clinical Global Impression
(CGI) and these data would be discussed in Abraham 1997. How-
ever, Abraham 1997 only retrospectively analysed the data on re-
sponders and non-responders; four participants responded, but it
was unclear from the report which groups they belonged to and the
CGI data for the dosage groups were also missing. We contacted
the main trialist who indicated he would provide the missing data,
but this has not been received at the time of writing. If we receive
this subsequently, we will include it in an update of this review.
Ongoing studies
We did not identify any ongoing studies.
Risk of bias in included studies
None of the studies explicitly described the allocation process fully.
Some of the studies were selective in presenting their data on
outcomes. Some of the outcomes in the trials could not be used and
we have not received missing data we requested from the authors
of the trials. Simpson 1999 was a trial sponsored by a clozapine
drug company. See Figure 3, Figure 4.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
20Clozapine dose for schizophrenia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 4. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All five studies were described as randomised. Allocation in Liu
2005 was via a random number generator. Simpson 1999, Sheng
1990, Chen 2013 and Chen 1998 did not describe the methods
used to generate the allocation sequence. None of the studies re-
ported on how the results of allocation were concealed.
Blinding
Simpson 1999 was described as a double-blind trial with assessors
blinded and all patients receiving the same number of identical
capsules every time, although the authors appear not to have tested
the success of blinding for participants or evaluators. This may
increase the risk of observer bias with potential for overestimation
of positive effects and underestimation of negative ones. Chen
1998 and Liu 2005 did not report if their trials were blinded.
Chen 2013 and Sheng 1990 did not report how blinding took
place. Blinding may be less important for objective outcomes such
as death, but the studies included here reported only subjective
outcomes.
Incomplete outcome data
Chen 1998, Chen 2013 and Sheng 1990 appear to have had no
loss to follow up. Liu 2005 reported on three participants who left
the study early with clear reasons for doing so. Simpson 1999 re-
ported the number leaving the study early and explicitly described
that their last observations were carried forward; however, data on
the scale for the Assessment of Negative Symptoms (SANS) were
not reported. de Leon 2007 reported data on patients who com-
pleted the Simpson 1999 trial. However the number of patients
on whom measures were reported differed slightly from week to
week, and it is unclear why the number of patients on whommea-
surements were reported at each week differed, who had missed
their measurements and why the measurements were not taken.
Selective reporting
Simpson 1999 did not report on SANS. Sheng1990 did not report
BPRS or TESS scores. Simpson 1999 reported responders’ and
non-responders’ data only at 48 weeks, which is after the cross-
over point at 16 weeks. No data is reported before the cross-over.
Effects of interventions
See: Summary of findings for the main comparison Clozapine:
very low dose (up to 149 mg/day) versus low dose (150 mg/day
to 300 mg/day) for schizophrenia; Summary of findings 2
Clozapine: very low dose (up to 149 mg/day) versus standard
dose (301 mg/day to 600 mg/day) for schizophrenia; Summary
of findings 3 Clozapine: low dose (150 mg/day to 300 mg/
day) versus standard dose (301 mg/day to 600 mg/day) for
schizophrenia
In the text below, data from Simpson 1999 have been adjusted
in accordance with the published corrections (Simpson 2001).
Specifically, the standard errors for BPRS-A endpoint scores which
were originally reported by the authors as if they were standard
deviations have been converted to standard deviations.
Comparison 1: clozapine: very low dose (up to 149
mg/day) versus low dose (150 mg/day to 300 mg/day)
1.1 Mental state: average endpoint scores (BPRS-A, high =
poor) - medium term
Simpson 1999 found no significant difference in endpoint mental
state scores at 16 weeks measured using the BPRS-A (n = 31, MD
3.55, 95% CI −4.50 to 11.60; Analysis 1.1).
1.2 Adverse effects: 1a. weight - BMI (kg/m²) - short term
Liu 2005 found no significant difference in BMI at the end of six
weeks in the very low dose group compared to the low dose group
(n = 59, MD −0.10, 95% CI −0.95 to 0.75; Analysis 1.2).
1.3 Adverse effects: 1b. weight gain (kg; average)
Simpson 1999 (reported in de Leon 2007) found no significant
difference between the groups in weight gain at week 12 (n =
27, 1 RCT, MD −1.10, 95% CI −3.93 to 1.73; Analysis 1.3).
There was similarly no significant difference between the groups
in weight gain at 16 weeks (n = 28, 1 RCT, MD −1.30, 95% CI
−4.86 to 2.26; Analysis 1.3).
1.4 Adverse effects: 1c. weight - body weight at endpoint (kg;
average) - short term
Liu 2005 found no significant difference in body weight between
the groups at the end of six weeks (n = 59, 1 RCT, MD 0.00, 95%
CI −3.92 to 3.92; Analysis 1.4).
One study, Liu 2005, reported on two other adverse effects.
1.5 Adverse effects: 2a. metabolic - blood glucose - before
and after meal
No difference between the groups were found before a meal (n =
59, 1 RCT, MD −0.40, 95% CI −1.06 to 0.26), one hour after
meal (n = 59, 1 RCT, MD −0.70, 95% CI −2.01 to 0.61), two
hours after meal (n = 59, 1 RCT, MD 0.30, 95% CI −0.98 to
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1.58) and three hours after meal (n = 59, 1 RCT, MD −0.70,
95% CI −1.59 to 0.19). There was no significant difference in
the overall analysis (n = 59, 1 RCT, MD −0.43, 95% CI −0.89
to 0.03; Analysis 1.5).
1.6 Adverse effects: 2b. metabolic - lipid profile - short term
Participants on low-dose clozapine had significantly lower serum
triglycerides than those on a very low dose (n = 59, 1 RCT, MD
1.00, 95% CI 0.51 to 1.49). Otherwise there was no significant
difference between the groups in terms of serum total cholesterol
(n = 59, 1 RCT, MD 0.50, 95% CI −0.12 to 1.12), high density
lipoprotein (HDL) (n = 59, 1 RCT, MD 0.04, 95% CI −0.14 to
0.22), low density lipoprotein (LDL) (n = 59, 1 RCT, MD 0.10,
95% CI−0.36 to 0.56), Apo-A1 (n = 59, 1 RCT, MD 0.05, 95%
CI −0.10 to 0.20) and Apo-B (n = 59, 1 RCT, MD 0.13, 95%
CI −0.16 to 0.42). All Analysis 1.6.
1.7 Leaving the study early
Simpson 1999 found no significant difference in numbers leav-
ing the study early between the groups in the medium term for
any reason (n = 31, 1 RCT, RR 6.00, 95% CI 0.31 to 115.56;
Analysis 1.7). Liu 2005 reported no significant difference between
the groups in the short term due to specific side effects (n = 60, 1
RCT, RR 0.33, 95% CI 0.01 to 7.87; Analysis 1.7). The overall
analysis showed no significant difference in the numbers leaving
the study early between the very low dose and the low-dose groups
in the short and medium term (n = 91, 2 RCTs, RR 1.50, 95%
CI 0.09 to 25.41; Analysis 1.7).
Missing outcomes
For this comparison, no studies reported on global state, death,
behaviour, functioning, quality of life, satisfaction with treatment,
service use and economic costs.
Comparison 2: clozapine: very low dose (up to 149
mg/day) versus standard dose (301 mg/day to 600
mg/day)
2.1 Mental state: average endpoint scores (BPRS-A, high =
poor) - medium term
Simpson 1999 found no significant difference in mean endpoint
BPRS-A scores at 16 weeks (n = 31, 1 RCT, MD 6.67, 95% CI
−2.09 to 15.43; Analysis 2.1).
2.2 Adverse effects: 1a. weight - BMI (in kg/m²) - short term
Liu 2005 foundno significant difference in bodymass index (BMI)
at the end of six weeks in the very low dose group compared to the
standard-dose group (n = 58, 1 RCT, MD 0.10, 95% CI −0.76
to 0.96; Analysis 2.2).
2.3 Adverse effects: 1b. weight - weight gain (kg; average)
Simpson 1999 (reported by de Leon 2007) found significantly
lower weight gain in the very low dose group at 12 weeks (n =
27, 1 RCT, MD −2.70, 95% CI −5.38 to −0.02), although no
significant difference between the groups at 16 weeks (n = 28, 1
RCT, MD −3.10, 95% CI −6.73 to 0.53; Analysis 2.3).
2.4 Adverse effects: 1c. body weight at endpoint - short term
(kg; average)
Liu 2005 found no significant difference in body weight between
the groups at six weeks (n = 58, 1 RCT, MD 1.00, 95% CI−2.66
to 4.66; Analysis 2.4).
2.5 Adverse effects: 2a. metabolic - blood glucose - short
term
Liu 2005 found that glucose level one hour after a meal was sig-
nificantly less in the very low dose group (n = 58, 1 RCT, MD
−1.60, 95%CI−2.90 to−0.30). There was no significant differ-
ence between the groups before meal (n = 58, 1 RCT, MD−0.10,
95% CI −0.68 to 0.48), two hours after meal (n = 58, 1 RCT,
MD −0.60, 95% CI −1.89 to 0.69) or three hours after meal (n
= 58, 1 RCT, MD−0.30, 95% CI−1.55 to 0.95). There was no
significant difference in the overall analysis between the groups (n
= 58, 1 RCT, MD −0.49, 95% CI −1.12 to 0.13). All Analysis
2.5.
2.6 Adverse effects: 2b. lipid profile - short term
Liu 2005 found that standard dose was associated with signifi-
cantly lower serum levels of total cholesterol (n = 58, 1 RCT, MD
1.00, 95% CI 0.20 to 1.80), triglycerides (n = 58, 1 RCT, MD
1.30, 95% CI 0.81 to 1.79) and Apo-B (n = 58, 1 RCT, MD
0.23, 95% CI 0.01 to 0.45). No significant difference was found
between the groups in high density lipoprotein (HDL) (n = 58, 1
RCT, MD 0.10, 95% CI−0.13 to 0.33), low density lipoprotein
(LDL) (n = 58, 1 RCT,MD0.00, 95%CI−0.39 to 0.39) or Apo-
A1 levels (n = 58, 1 RCT, MD 0.04, 95% CI −0.10 to 0.18). All
Analysis 2.6.
2.7 Leaving the study early
Simpson 1999 found no significant difference in numbers leaving
the study early for any reason between the groups in the medium
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term (n = 31, 1 RCT, RR 1.21, 95% CI 0.20 to 7.55). Liu 2005
reported no significant difference between the groups in numbers
leaving the study early due to specific physical side effects in the
short term (n = 60, 1 RCT, RR 0.20, 95% CI 0.01 to 4.00).
The overall analysis showed no significant difference between the
groups (n = 91, 2 RCTs, RR 0.73, 95% CI 0.14 to 3.72; Analysis
2.7).
Missing outcomes
For this comparison, no studies reported on global state, death,
behaviour, functioning, quality of life, satisfaction with treatment,
service use and economic costs.
Comparison 3: clopazine: low dose (150 mg/day to
300 mg/day) versus standard dose (301 mg/day to 600
mg/day)
3.1 Mental state: 1a. clinically important response (BPRS
score > 30% change)
Chen1998 foundno significant difference in curative rate between
the groups (n = 176, 1 RCT, RR 0.93, 95% CI 0.78 to 1.10;
Analysis 3.1).
3.2 Mental state: 1b. average endpoint score (BPRS-A total,
high = poor)
Chen 1998 reported no significant difference between the groups
for total scores at week 6 (n = 176, 1 RCT, MD 1.70, 95% CI
−1.26 to 4.66; Analysis 3.2). Simpson 1999 reported no signifi-
cant difference between the groups for total scores at 16 weeks (n
= 34, 1 RCT, MD 3.12, 95% CI −4.20 to 10.44; Analysis 3.2).
3.3 Mental state: 1c. average endpoint score (BPRS-A,
subscores, high = poor)
3.3.1 Anxiety
Chen 1998 found no significant difference between the groups
at week 6 (n = 176, 1 RCT, MD 0.00, 95% CI −0.09 to 0.09;
Analysis 3.3).
3.3.2 Blunted Affect
Chen 1998 found no significant difference between the groups
at week 6 (n = 176, 1 RCT, MD 0.00, 95% CI −0.18 to 0.18;
Analysis 3.3).
3.3.3 Conceptual Disorganisation
Chen 1998 found no significant difference between the groups
at week 6 (n = 176, 1 RCT, MD 0.20, 95% CI −0.02 to 0.42,
Analysis 3.2.5).
3.3.4 Excitement
Chen 1998 found no significant difference between the groups
at week 6 (n = 176, 1 RCT, MD 0.00, 95% CI −0.10 to 0.10;
Analysis 3.3).
3.3.5 Uncooperativeness
Chen 1998 found no significant difference between the groups
at week 6 (n = 176, 1 RCT, MD 0.00, 95% CI −0.21 to 0.21;
Analysis 3.3).
3.4 Mental state: 1d. clinical improvement (clinician
assessed)
There was no significant difference between groups at 12 weeks
(Chen 1998; Chen 2013) (n = 141, 2 RCTs, RR 0.76, 95% CI
0.36 to 1.61; Analysis 3.4).
3.5 Adverse effects: 1a. weight - BMI (in kg/m²) - short term
Liu 2005 found no significant difference in body mass index at the
end of six weeks in the low dose group compared to the standard
dose group (n = 57, 1 RCT, MD 0.20, 95% CI −0.84 to 1.24;
Analysis 3.5)
3.6 Adverse effects: 1b. weight - weight gain (kg; average)
Simpson 1999 (reported in de Leon 2007) found no significant
difference in weight gain between the groups at week 12 (n = 30,
1 RCT, MD −1.60, 95% CI −4.47 to 1.27) or week 16 (n = 30,
MD −1.80, 95% CI −5.38 to 1.78; Analysis 3.6).
3.7 Adverse effects: 1c. body weight at endpoint (kg;
average) - short term
Liu 2005 found no significant difference in body weight between
the groups in the short term (n = 57, 1 RCT, MD 1.00, 95% CI
−3.42 to 5.42; Analysis 3.5.4).
3.8 Adverse effects: 2a. metabolic - blood glucose - short
term
Liu 2005 found no significant difference in glucose levels between
the groups before meal (n = 57, 1 RCT, MD 0.30, 95% CI−0.23
to 0.83; Analysis 3.8), one hour after meal (n = 57, 1 RCT, MD
−0.90, 95%CI−2.33 to 0.53; Analysis 3.8), two hours aftermeal
(n = 57, 1 RCT, MD −0.90, 95% CI −2.14 to 0.34; Analysis
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3.8), three hours after meal (n = 57, 1 RCT, MD 0.40, 95% CI
−0.84 to 1.64; Analysis 3.8). There was no difference between
the groups in the overall analysis (1 RCT, MD −0.12, 95% CI
−0.79 to 0.56; Analysis 3.8).
3.9 Adverse effects: 2b. metabolic - lipid profile - short term
Liu 2005 found no significant difference between the groups in
serum total cholesterol (n = 57, 1 RCT, MD 0.50, 95% CI−0.29
to 1.29; Analysis 3.9), triglycerides (n = 57, 1RCT,MD0.30, 95%
CI −0.12 to 0.72; Analysis 3.9), high density lipoprotein (HDL)
(n = 57, 1 RCT, MD 0.06, 95% CI −0.16 to 0.28; Analysis 3.9),
low density lipoprotein (LDL) (n = 57, 1 RCT, MD−0.10, 95%
CI −0.50 to 0.30; Analysis 3.9), Apo A-1 (n = 57, 1 RCT, MD
−0.01, 95% C −0.14 to 0.12; Analysis 3.9) and Apo-B levels (n
= 57, 1 RCT, MD 0.10, 95% CI −0.14 to 0.34; Analysis 3.9).
3.10 Adverse effects: 3. various effects - short term
Chen 1998 found a significantly greater incidence in the standard
compared to the low dose group for lethargy (n = 176, RR 0.77,
95% CI 0.60 to 0.97; Analysis 3.10), hypersalivation (n = 176,
RR 0.70, 95% CI 0.57 to 0.84; Analysis 3.10), dizziness (n = 176,
RR 0.56, 95% CI 0.39 to 0.81; Analysis 3.10) and tachycardia (n
= 176, RR 0.57, 95% CI 0.45 to 0.71; Analysis 3.10).
3.11 Adverse effects: 4. average endpoint score (TESS, high
= poor) - short term
Meta-analysis of two studies, Chen 1998 and Chen 2013, found
total TESS scores were significantly lower in the low-dose group
compared to standard dose (n = 124, 2 RCTs, MD −3.99, 95%
CI−5.75 to−2.24; Analysis 3.11). Chen 1998 found that TESS
scores were significantly lower in the low-dose group compared
to standard dose on sub scores for behavioural toxicity (n = 176,
1 RCT, MD −1.00, 95% CI −1.51 to −0.49; Analysis 3.11),
vegetative nervous system (n = 176, 1 RCT, MD −0.90, 95%
CI −1.61 to −0.19; Analysis 3.11) and cardiovascular system (n
= 176, 1 RCT, MD −0.60, 95% CI −0.98 to −0.22; Analysis
3.11).
3.12 Leaving the study early
For this comparison, no participant left the study early in Chen
1998. Simpson 1999 found no significant difference in numbers
leaving the study early for any reason between the groups in the
medium term (n = 34, 1 RCT, RR 0.20, 95% CI 0.01 to 3.88;
Analysis 3.12). Liu 2005 found no significant difference in num-
bers leaving the study early between the groups in the short term
due to specific side effects (n = 60, 1 RCT, RR 0.50, 95% CI
0.05 to 5.22; Analysis 3.12). There was no difference between the
groups in the overall analysis (n = 47, 2 RCTs, RR 0.35, 95% CI
0.06 to 2.21; Analysis 3.12).
Missing outcomes
For this comparison, no studies reported on global state, death,
behaviour, functioning, quality of life, satisfaction with treatment,
service use and economic costs.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
CLOZAPINE: VERY LOW DOSE (up to 149 mg/ day) versus STANDARD DOSE (301-600 mg/ day) for schizophrenia
Patient or population: pat ients with schizophrenia
Settings:
Intervention: Clozapine: very low dose (up to 149 mg/ day) versus standard dose (301 mg/ day to 600 mg/ day)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Clozapine: very low
dose (up to 149 mg/
day) versus standard
dose (301 mg/ day to
600 mg/ day)
Global state: clinically
important response, as
defined by individual
studies
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
M ental state: clinically
important response, as
defined by individual
studies *
Follow-up: 16 weeks
The mean clinical re-
sponse: mental state
- average scores -
medium term end-
point (BPRS-A, high =
worse) in the interven-
t ion group was
6.67 higher
(2.09 to 15.43 higher)
31
(1 study)
⊕©©©
very low1,2,3
* Pre-def ined outcome
not reported: Mental
state measured as av-
erage endpoint scores
(BPRS-A, high = worse)
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Functioning: clinically
important change in
general functioning, as
defined by individual
studies
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Adverse effect: clin-
ically important ad-
verse effect (weight -
BM I)
Follow-up: 6 weeks
The mean adverse ef -
fect - any clinically
important specif ic ad-
verse ef fects - BMI in
the intervent ion group
was
0.1 higher
(0.76 lower to 0.96
higher)
58
(1 study)
⊕⊕©©
low2,3
Service use: number of
days hospitalised
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Service use: time to
hospitalisation
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Quality of life: clini-
cally important change
in general quality of life
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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1 Risk of bias: rated as ’serious’ (downgraded by 1) due to attrit ion bias, report ing bias, and sponsorship by Novart is
Pharmaceut icals.
2 Indirectness: rated ’serious’ (downgraded by 1) as proxy measure of pre-def ined outcome
3 Imprecision: rated ’serious’ (downgraded by 1) as only one study providing data, small number of part icipants (less than
200)
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Clozapine: low dose (150 mg/ day to 300 mg/ day) versus standard dose (301 mg/ day to 600 mg/ day) for schizophrenia
Patient or population: pat ients with schizophrenia
Settings:
Intervention: Clozapine: low dose (150 mg/ day to 300 mg/ day) versus standard dose (301 mg/ day to 600 mg/ day)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Clozapine: low dose
(150 mg/ day to 300
mg/ day) versus stan-
dard dose (301 mg/ day
to 600 mg/ day)
Global state: clinically
important response, as
defined by individual
studies
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
M ental state: clinically
important response in
mental state
BPRS score >30%
change
Follow-up: 6 weeks
Low1 RR 0.93
(0.78 to 1.1)
176
(1 study)
⊕⊕©©
low 1,3
200 per 1000 186 per 1000
(156 to 220)
M oderate1
500 per 1000 465 per 1000
(390 to 550)
High1
800 per 1000 744 per 1000
(624 to 880)
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Functioning: clinically
important change in
general functioning, as
defined by individual
studies
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Adverse effect: clin-
ically important ad-
verse effect ( weight -
BM I)
Follow-up: 6 weeks
The mean adverse ef -
fect - any clinically
important specif ic ad-
verse ef fects - BMI in
the intervent ion group
was
0.2 higher
(0.84 lower to 1.24
higher)
57
(1 study)
⊕⊕©©
low2,3
Service use: number of
days hospitalised
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Service use: time to
hospitalisation
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Quality of life: clini-
cally important change
in general quality of life
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Risk of bias rated as ’serious’ (downgraded by 1) as allocat ion concealment, blinding status and trial sponsorship unclear3
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2 Indirectness: rated ’serious’ (downgraded by 1) as proxy measure of pre-def ined outcome
3 Imprecision: rated as ’serious’ (downgraded by 1) as only one study providing data, small number of part icipants (less than
200)
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D I S C U S S I O N
Summary of main results
We included five studies with data from 452 participants suffering
from schizophrenia and schizoaffective disorders diagnosed by any
criteria.We categorised doses of clozapine into five categories: very
low dose clozapine: up to 149 mg/day; low-dose clozapine: 150
mg/day to 300 mg/day; standard-dose clozapine: 301 mg/day to
600 mg/day; high-dose clozapine: 601 mg/day to 900 mg/day;
and very high dose clozapine: 901 mg/day and above. Simpson
1999 compared the effects of clozapine at doses of 100 mg/day
(very low), 300 mg/day (low dose) and 600 mg/day (standard
dose) over both short term (up to 12 weeks) and medium term (16
weeks). Chen 2013 compared doses of 200 mg/day to 300 mg/
day, 301 mg/day to 400 mg/day, and 401 mg/day to 500 mg/day
over 12 weeks. Sheng 1990 compared doses of 300 mg/day and
600 mg/day over 12 weeks. Liu 2005 compared effects of three
different doses of clozapine: less than 150 mg/day (very low dose);
150 mg/day to 300 mg/day (low dose); and more than 300 mg/
day (standard) over short term.
Liu 2005 reported over six weeks on outcomes including leaving
the study early, body weight, body mass index (BMI), lipid profile
and blood glucose levelsmeasured before meals, and one hour, two
hours and three hours after meals. Chen 2013 reported on mental
state as clinical improvement (clinician assessed), and on TESS
scale scores. Outcomes reported by Sheng 1990 were mental state
as clinical improvement (clinician assessed), but the authors did
not report BPRS scores or TESS scale scores.
Chen 1998 compared clozapine at doses of 200 mg/day (low dose)
and 500 mg/day (standard dose) in short-term and reported data
over six weeks on outcomes including global state on clinically
important response as defined by individual studies (curative rate:
BPRS score < 30% change = no improvement), mental state on the
Brief Psychiatric Rating scale-Anchored (BPRS-A) and subscores
of this scale, and adverse reaction using the TESS scale and the
incidence of lethargy, hypersalivation, dizziness, and tachycardia.
Simpson 1999 reported on leaving the study early, BPRS-A total
scores. Though their report stated that they measured CGI and
SANS, these datawere not reported in the paper.Data on end body
weight, weight gain and BMI over shorter term and medium term
were reported in de Leon 2007. Data on BMI could not be used as
it was not presented according to doses. We also could not use data
on “clinically important response as defined by individual studies”
as the details of responders were presented only at 48 weeks and
not at 16 weeks (before cross-over). In addition, it is reported that
four people responded at end of 16 weeks, but it is unclear which
dosage group these four patients belonged to. Simpson 1999 stated
that data on CGI would be discussed in Abraham 1997, but we
found this was not the case. We contacted the author for data
on CGI, SANS, data on responders at 16 weeks and the details
on which arm the four responders belonged to but we have not
received the data at the time of writing.
There were no studies comparing high dose or very high dose of
clozapine and none of the reports identified presented outcomes
in the longer term.
1 Comparison: clozapine: very low dose (up to 149
mg/day) versus low dose (150 mg/day to 300 mg/day)
Short term
We found no evidence relating to clinical response. In terms of ad-
verse effects, in one RCT of 59 participants there was no difference
between the groups in BMI at endpoint with the very low dose
group only 0.1 lower (0.95 lower to 0.75 higher) (Liu 2005). On
other outcomes, the same study found low-dose clozapine asso-
ciated with lower serum triglycerides compared to very low dose,
but no differences between the groups in other elements of the
lipid profile, in blood glucose levels, in body weight at endpoint
or in leaving the study early.
Medium term
We found no evidence relating to clinical response. In one small
RCT of 31 participants (Simpson 1999), there was no difference
between the groups in average BPRS-A scores and no difference
on change in mental state score. On other outcomes, no difference
was found between the groups in terms of weight gain or number
leaving the study early (Simpson 1999).
2 Comparison: clozapine: very low (up to 149 mg/day)
versus standard dose (301 mg/day to 600 mg/day)
Short term
We found no evidence relating to clinical response in the short
term. In terms of adverse effects, in one RCT of 58 participants
there was no difference between the groups in BMI at endpoint
with the very low dose group only 0.1 higher (0.76 lower to 0.96
higher) (Liu 2005). There was no difference in body weight at
endpoint in the same study, although the very low dose group had
less weight gain than the standard-dose group at six and 12 weeks.
On other outcomes, we found evidence in one study that the
very low dose group had lower glucose levels one hour post meal
compared to the standard-dose group, but otherwise there was no
difference between the groups in blood glucosemeasurements (Liu
2005); and no difference between the groups in numbers leaving
the study early. In the same study, at six weeks standard dose was
associated with lower serum triglycerides, serum total cholesterol
and Apo-B, but otherwise there was no difference between the
groups in terms of lipid profile (Liu 2005). These results should
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be interpreted with caution as this trial was conducted only for six
weeks with a small number of participants.
Medium term
We found no evidence relating to clinical response in the medium
term. On other outcomes, no differences between the groups were
found in the medium term for weight gain or numbers leaving the
study early (Simpson 1999).
3. Comparison: clozapine: low dose (150 mg/day to
300 mg/day) versus standard dose (301 mg/day to 600
mg/day)
Short term
We found no evidence relating to clinical response or to clinically
significant response in global state in the short term. In one RCT
of 57 participants there was no difference between the groups in
BMI at endpoint with the low-dose group only 0.2 higher (0.84
lower to 1.24 higher) (Liu 2005). On other outcomes, there was
no difference between the groups on body weight at endpoint,
lipid profile or blood glucose measurements. Side effects measured
by TESS were less in the low-dose group in two studies (Chen
1998; Chen 2013), and the incidence of lethargy, hypersalivation,
dizziness and tachycardia were also less in the low-dose group in
one study (Chen 1998).
Medium term
We found no evidence from one RCT of 34 participants that
mental state at endpoint, numbers leaving the study early orweight
gain differed between the groups (Simpson 1999).
4. Missing outcomes
There was no information available on other important outcomes
such as clinically significant response in social or life skills, relapse,
prolactin increase, service use, satisfaction with care or quality of
life.
5. Summary
We identified just three randomised controlled trials that met our
inclusion criteria. We looked at a range of different doses includ-
ing very low (up to 149 mg/day), low (150 mg/day to 300 mg/
day), standard (301 mg/day to 600 mg/day), high (601 mg/day
to 900 mg/day) and very high (901 mg/day and above). All trials
identified compared very low dose, low dose and standard dose
only. No trials were identified comparing high dose or very high
dose to standard dose. Two studies were only of six weeks’ and two
were of 12 weeks’ duration; one study relates to a trial of 48 weeks,
but only for a 16-week period before crossing over. The data for
a number of outcomes could not be extracted. Four of the five
included studies were based on a small number of participants.
The quality of the evidence available was judged very low to low,
and the following findings should be interpreted cautiously. We
found no evidence relating to clinical response in the short or
medium term. At the end of six weeks, incidence of lethargy, hy-
persalivation, dizziness and tachycardia was lower at low- com-
pared to standard-dose regimes; also side effects as measured by
the Treatment Emergent Side Effect Scale (TESS) were less at low
compared to standard dose. At six weeks, very low dose was as-
sociated with lower levels of blood glucose one hour post meal
than standard dose and weight gain was the least in this group. At
six weeks, standard dose was associated with lower serum triglyc-
erides, serum total cholesterol and Apo-B than very low dose, and
low-dose recipients had lower serum triglycerides than those on
very low dose. This might suggest that the lipid variation may not
be associated with doses of clozapine in the short term, such as
six weeks’ duration, but more trials are needed to validate the side
effects of clozapine long term
Overall completeness and applicability of
evidence
Completeness
We suggest that the studies identified are insufficient to clearly
identify what dose of clozapine is optimal for people suffering
from schizophrenia and schizophreniform psychosis to gain a de-
sired response to illness, attain remission and experience an im-
proved quality of life. Important information on outcomes rele-
vant to clinicians, consumers and policy makers (such as relapse,
remission, social functioning and quality of life, service utilisation,
cost-effectiveness, satisfaction with care, and quality of life) is not
currently available.
Applicability
The five studies in our review reported on 14 outcomes and only
on short-term andmedium-term durations. We could not identify
any studies which compared high and very high doses of clozapine
or which considered outcomes long term. This can lead to diffi-
culties in generalising our findings in the management of chronic
illness such as schizophrenia. The evidence appears to be incom-
plete and there are various limitations in the applicability of the
results from our review.
Quality of the evidence
The quality of the evidence was poor. Only one of the included
studies was clearly described as a double blind trial; the other
studies were not clear about blinding status. In addition, data were
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selectively reported in some papers, which raises the possibility of
bias. The quality of the evidence was also limited by the small
number of participants reported on by Simpson 1999 (n = 31),
Chen 2013 (n = 90), Sheng 1990 (n = 51) and Liu 2005 (n =
59). It is also of concern that two trials were conducted only for
six weeks. Schizophrenia is a chronic illness and medications such
as clozapine would need to be prescribed for a longer period of
time so that these results may not generalise in the longer term.
More good-quality trials are therefore needed to allow findings to
be substantiated and firm conclusions to be drawn.
Potential biases in the review process
We are not aware of any flaws in our review process. The search
for trials was thorough and the review authors followed the criteria
prespecified in the protocol. It is always possible, however, that we
could have failed to identify relevant studies.
Agreements and disagreements with other
studies or reviews
To our knowledge there has been no other systematic review or
meta-analysis comparing different doses of clozapine.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with schizophrenia
We foundno evidence relating dose to clinical response in the short
or medium term. A standard dose (301 mg/day to 600 mg/day)
helps in improvement of illness but causes more adverse effects
than lower doses. Evidence from our review indicates that the
very low dose of clozapine (< 150 mg/day) is associated with least
side effects. Evidence supports that the low dose (150 mg/day to
300 mg/day) could be the optimal dose to see a clinical response
with fewest side effects. Standard dose appears to be associated
with more side effects than the other two groups which might
necessitate close monitoring of weight, lipid profile and glucose.
We could not reach a conclusion on high dose and very high dose
of clozapine. Hence, in practice, every patient needs to be titrated
on the most appropriate dose of clozapine necessary to gain a
response, guided by closemonitoring for emergence of side effects.
2. For clinicians
Based on effects on mental state, we found no evidence on the
optimal dosing of clozapine. Careful consideration has to be given
to balancing the advantages and disadvantages of different dosing
schemes, in particular in relation to side effects which seem to be
lower at lower doses. We were unable to identify any trials on high
and very high doses of clozapine.
3. For managers or policy makers
More studies are needed to replicate and validate findings so far,
and to ascertain effects on outcomes such as relapse, remission,
social functioning, quality of life, service utilisation, cost-effective-
ness, satisfaction with care, quality of life. There is a particular lack
of medium- or long-term outcome data and on above-standard
dosing regimes.
Implications for research
1. General
Much more data would have been available if the recommenda-
tions of the CONSORT statement had been anticipated by the
trialists (Moher 2001). Allocation concealment is essential for the
result of a trial to be considered valid and gives the assurance that
selection bias is kept to the minimum. Well-described and tested
blinding could have encouraged confidence in the control of per-
formance and detection bias. It is also important to know how
many, and from which groups, people were withdrawn in order to
evaluate exclusion bias. It would also have been helpful if authors
had presented data in a useful manner which reflects association
between intervention and outcome, for example relative risk, odds
ratio, risk or mean differences, as well as raw numbers. Binary out-
comes should be calculated in preference to continuous results, as
they are easier to interpret. If P values are used, the exact value
should be reported.
2. Specific
2.1 Reviews
Inspection of the table of excluded studies does not suggest any
particular need for additional review topics in relation to clozapine
dose since data from any new eligible report will be included in
updates of this review.
A number of the excluded studies examined adverse effects of
clozapine at differing dose regimes, but could not be included
because they reported results by serum clozapine level and not
by clozapine dose. There may therefore be value in additionally
reviewing those studies that focus on serum clozapine levels under
a separate or modified protocol.
Excluded studies in relation to other Cochrane Reviews
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Excluded study Comparison Existing Cochrane review
de Leon 1995a Akathisia at three clozapine dose levels None currently
de Leon 2003 Muscarinic side effects at three clozapine dose levels None currently
de Leon 2004 Serum prolactin level at three clozapine dose levels None currently
Han 2001 Two different dose levels of clozapine with an adjunc-
tive medication (sulpiride)
Wang 2010
Liu 2005 BPRS and TESS scores at three clozapine dose levels None currently
Nair 1998 Those with and without probable tardive dyskinesia at
three clozapine dose levels
None currently
Nair 1999 Those with and without probable tardive dyskinesia at
three clozapine dose levels
None currently
Potkin 1993 BPRS, CGI & EPS scores at two clozapine dose levels None currently
Potkin 1994 BPRS scores at two clozapine dose levels None currently
Tang 2000 Clinical response at three plasma clozapine concentra-
tion levels
None currently
VanderZwaag 1996 BPRS scores at three different serum clozapine levels. None currently
VanderZwaag 1997 BPRS scores at three different serum clozapine levels. None currently
2.2 Trials
Clozapine is usually reserved for people suffering from treatment-
resistant illnesses. In spite of clozapine being in use for a very long
time, there are still insufficient trials to clearly evidence which dose
of clozapine is optimal for people suffering from schizophrenia
and schizophreniform psychosis, to gain response to illness, attain
remission and improve quality of life.
We consider an ‘ideal’ study might have the following character-
istics.
• Participants: adults diagnosed with schizophrenia or
schizoaffective disorder. Random allocation with 150
participants per arm and 100% follow-up.
• Intervention: three contrasting levels of clozapine dose -
high (601 mg/day to 900 mg/day), standard (301 mg/day to 600
mg/day) and low (150 mg/day to 300 mg/day).
• Blinding: participants, clinical staff and researchers blinded
to allocation status.
• Outcomes: functioning (clinically significant response in
social or life skills), clinical response (e.g. clinically significant
response in mental state), service utilisation (e.g. time to
hospitalisation, number of days hospitalised), quality of life,
relapse, satisfaction with care, and any clinically important
adverse effects (e.g. weight gain, prolactin increase).
A C K N OW L E D G E M E N T S
The Cochrane Schizophrenia Group Editorial Base in Notting-
ham produces and maintains standard text for use in the Methods
section of their reviews. We have used this text as the basis of what
appears here and adapted it as required.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chen 1998
Methods Allocation: randomly assigned (no further details).
Blinding: not stated.
Duration: six weeks.
Setting: unclear.
Participants Diagnosis: schizophrenia.
N = 176.
Age: 17 to 55 years.
Sex: male and female (numbers not given)
Racial origin: unclear.
Consent: unclear.
History: Average length of illness: 8 ± 11months.
Interventions 1. Clozapine: dose 200 mg/day. N = 94.
2. Clozapine: dose 500 mg/day. N = 82.
Outcomes Global state: Clinically important response as defined by individual studies (BPRS score
> 30% change).
Mental state: average endpoint score and average change score B (BPRS-A).
Adverse effects: TESS scores, lethargy, hypersalivation, dizziness, tachycardia
Leaving the study early.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned, no further details.
Allocation concealment (selection bias) Unclear risk No details.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data reported; no loss to follow up.
Selective reporting (reporting bias) Low risk No indication of selective reporting.
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Chen 1998 (Continued)
Other bias Unclear risk Sponsor unclear.
Chen 2013
Methods Allocation: randomised, method not stated
Blinding: double blind, no further details
Duration: twelve weeks.
Setting: not stated
Participants Patients with schizophrenia (inpatients; male & female)
Interventions 1. Clozapine: dose 200-300 mg/day. N = 30
2. Clozapine: dose 301-400 mg/day. N = 30
3. Clozapine: dose 401-500 mg/day. N = 30
Initial dose 25 mg/day in all cases: doses above achieved at 2-3 weeks
Outcomes Mental state: Clinical improvement, clinician assessed
Adverse effects: TESS scale score
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned, no further details.
Allocation concealment (selection bias) Unclear risk No details.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data reported; no loss to follow up.
Selective reporting (reporting bias) Low risk No indication of selective reporting.
Other bias Unclear risk Sponsor unclear.
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Liu 2005
Methods Allocation: randomised using random number table
Blinding: not stated.
Duration: six weeks.
Setting: inpatient setting at a medical College.
Participants Diagnosis: schizophrenia (CCMD-3)
N = 87.
Age: 18 to 45 years.
Sex: 87 M.
Racial origin: unclear.
Consent: unclear.
History: information not available.
Interventions 1. Clozapine: dose < 150 mg/day. N = 30.
2. Clozapine: dose 150 to 300 mg/day. N = 29.
3. Clozapine: dose > 300 mg/day. N = 28.
Outcomes Adverse effects: serum lipid level before and after treatment, body weight, BMI.
Leaving the study early*.
Notes * Standard dose group: two participants left the study early (due to neutropenia and
tachycardia). Low dose group: one participant left the study early (due to increased level
of Alanine aminotransferase)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation by random number table.
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Three participants left the study early, rea-
sons given.
Selective reporting (reporting bias) Low risk No indication of selective reporting.
Other bias Low risk No indication of other bias.
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Sheng 1990
Methods Allocation: randomised, method not stated.
Blinding: double blind, no further details.
Duration: twelve weeks.
Setting: not stated.
Participants Patients with schizophrenia (inpatients; male & female).
Interventions 1.Clozapine (capsule): dose 300 mg/day. N = 25.
2.Clozapine (capsule): dose 600 mg/day. N = 26.
Outcomes Mental state: Clinical improvement, clinician assessed.
Mental state: BPRS score (data not available).
Adverse effects: TESS scale score (data not available).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned, no further details.
Allocation concealment (selection bias) Unclear risk No details.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk ‘Double blind’, no further details.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk ‘Double blind’, no further details.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data reported; no loss to follow-up.
Selective reporting (reporting bias) High risk BPRS and TESS score data not available.
Other bias Unclear risk Sponsor unclear.
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Simpson 1999
Methods Allocation: implied randomisation trial, no details on method of allocation.
Blindness: double-blind, assessors blind to clozapine doses.
Duration: 16 weeks (first phase before cross over lasted 16 weeks; total of three phases
lasting 48 weeks).
Setting: Research ward, State Hospital Clinical Research Centre, USA
Participants Diagnosis: treatment refractory schizophrenia or schizoaffective disorder (DSM-III-R).
N = 48 (number who completed first 16 weeks before any cross-over).
Age: 35 to 54 years.
Sex: M 22, F 28.
Racial origin: Caucasian 43, African American 7.
Consent: signed informed consent.
History: average length of illness: mean 25.1 years (range 1 to 38 years), median of five
psychiatric hospitalizations (range 1 to 25); patients had not shown satisfactory clinical
response to treatment with at least three antipsychotic drugs (each given for at least six
weeks in doses equivalent to 1000 mg/day of chlorpromazine)
Interventions 1. Clozapine: dose 100 mg/day. N = 14.
2. Clozapine: dose 300 mg/day. N = 17.
3. Clozapine: dose 600 mg/day. N = 17.
Outcomes Mental state: (BPRS-A) total score.
Leaving the study early.
Notes 1. Patients stayed in research centre for four weeks for adaptation (naturalistic baseline
with no modification in their treatment regimen). Before first phase of clozapine treat-
ment, patients underwent a four-week haloperidol treatment and then a one-week wash
out. We contacted the main trialist to obtain missing data on CGI, SANS, responders
at 16 weeks, and on which dosage group the four responders belonged to but we have
not received results at the time of writing
2. data from Simpson 1999 have been adjusted in accordance with the published cor-
rections (Simpson 2001). Specifically, the standard errors for BPRS-A endpoint scores
which were originally reported by the authors as if they were standard deviations have
been converted to standard deviations
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Implied randomisation trial, no details on
method of allocation
Allocation concealment (selection bias) Unclear risk No details.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants were blinded to doses of cloza-
pine; no details on personnel giving the
treatment
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Simpson 1999 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to doses of clozap-
ine.
Incomplete outcome data (attrition bias)
All outcomes
High risk 44 out of 48 patients completed the first 16
weeks of the trial; four patients had their
last observation carried forward. If a patient
had attained the maximum assigned dose
for two weeks, his or her data were carried
forward for end-point analysis. However,
as clozapine can take more time to exert its
effect, if the patient leaves the study soon
after two weeks, the last observation carried
forwardmight underestimate the efficiency
of that particular dose of clozapine
Selective reporting (reporting bias) High risk Responders’ data reported at 48 weeks, but
not at end of 16 weeks and 32 weeks by
dose; CGI, SANS not reported
Other bias High risk Sponsored by Novartis Pharmaceuticals.
BPRS: Brief Psychiatric Rating Scale
BPRS-A: Brief Psychiatric Rating Scale - Anchored
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Borges 2010 Allocation: random allocation.
Participants: all had schizophrenia.
Intervention: examined bioavailability at a clozapine dose regime of between 200 mg/day and 800 mg/day
Outcome: no additional data for this review; study examined only the bioavailability of clozapine
de Leon 1995a Allocation: method of allocation unclear.
Participants: all had schizophrenia or schizoaffective disorder
Intervention: compared akathisia at three clozapine doses of 100mg/day, 300mg/day & 600mg/day
Outcomes: Barnes akathisia scale endpoint and change scores unavailable
de Leon 1995b Allocation: random allocation.
Participants: all had treatment refractory schizophrenia or schizoaffective disorder
Intervention: three clozapine doses of 100 mg/day, 300 mg/day and 600 mg/day
Outcome: no additional data for this review; these 4 studies examined (a) relationship between tardive dyski-
nesia and extrapyramidal symptoms, (b) coefficients of variation in the relationship between dose and plasma
46Clozapine dose for schizophrenia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
concentration levels, (c) plasma cotinine levels, and (d) effects of haloperidol
de Leon 2003 Allocation: method of allocation unclear.
Participants: all had schizophrenia or schizoaffective disorder
Intervention: compared muscarinic side effects at three clozapine doses of 100mg/day, 300mg/day & 600mg/
day
Outcomes: no usable data before the first cross-over.
de Leon 2004 Allocation: method of allocation unclear.
Participants: all had schizophrenia or schizoaffective disorder
Intervention: compared serum prolactin level at three clozapine doses of 100mg/day, 300mg/day & 600mg/
day
Outcomes: no usable data before the first cross-over.
Guo 2003 Allocation: non-randomized controlled trial.
Participants: all had schizophrenia.
Intervention: studied BEAM changes after taking three different dosages of clozapine: < 150 mg/day vs 150
mg/day to 400 mg/day vs > 400 mg/day
Outcomes: BEAM changes.
Han 2001 Allocation: random allocation.
Participants: all had schizophrenia.
Intervention: two clozapine doses of < 300mg/day & > 300mg/day, but adjunctive medication (sulpiride) not
held constant between different clozapine dosage groups
Outcomes: compared BPRS and TESS scores between groups.
Liu 2005a Allocation: not allocated at random.
Participants: all had schizophrenia.
Intervention: three different clozapine doses.
Outcomes: compared PANSS scores and p300 test results.
Matz 1974 Allocation: not randomised; allocation at discretion of psychiatrists in charge
Participation: all had schizophrenia.
Intervention: examined effects of clozapine at two doses (up to 100 mg t.i.d. and up to 400 mg t.i.d.)
Outcome: BPRS and NOSIE, plus TES for adverse effects.
McEvoy 1995 Allocation: random allocation.
Participants: all had schizophrenia.
Intervention: examined BPRS, CGI, smoking measures & EEG changes at three clozapine serum level ranges
(50 ng/mL to 150 ng/mL, 200 ng/mL to 300 ng/mL & 350 ng/mL to 450ng/mL)
Outcome: no additional data for this review; comparison was by serum clozapine level, and not by clozapine
dose
McEvoy 1996 Allocation: random allocation.
Participants: all had chronic schizophrenia.
Intervention: examined smoking measures at three clozapine serum level ranges (50 ng/mL to 150ng/mL, 200
ng/mL to 300ng/mL & 350 ng/mL to 450ng/mL)
Outcome: no additional data for this review; comparison was by serum clozapine level, and not by clozapine
dose
47Clozapine dose for schizophrenia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Nair 1998 Allocation: random allocation.
Participants: all had treatment refractory schizophrenia or schizoaffective disorder
Intervention: three clozapine doses of 100 mg/day, 300 mg/day and 600 mg/day
Outcome: no additional data; study compared those with andwithout probable tardive dyskinesia in a subgroup
of 23 participants from the Simpson 1999 trial.
Nair 1999 Allocation: random allocation.
Participants: all had treatment refractory schizophrenia or schizoaffective disorder
Intervention: three clozapine doses of 100 mg/day, 300 mg/day and 600 mg/day
Outcome: no additional data; study compared those with andwithout probable tardive dyskinesia in a subgroup
of 33 participants from the Simpson 1999 trial.
Potkin 1993 Allocation: random allocation.
Participants: all had chronic schizophrenia.
Intervention: compared BPRS, CGI & EPS scores at two clozapine doses of 400mg/day & 800mg/day
Outcomes: data limited to the ’first 25’ patients with no information on which dosage group they belonged
to; attempts to contact first author unsuccessful
Potkin 1994 Allocation: random allocation.
Participants: all had schizophrenia.
Intervention: clozapine commenced at 400mg/daywith participants randomised at end of week four to 400mg/
day or 800mg/day. Study compared dosage groups on BPRS scores and numbers discontinuing in the first
three weeks
Outcomes: compared BPRS scores by serum clozapine level, and not by clozapine dose; attempts to contact
first author unsuccessful
Tang 2000 Allocation: not randomly allocated.
Participants: all had schizophrenia.
Intervention: examined the relationship between plasma clozapine concentration and clinical response
VanderZwaag 1996 Allocation: random allocation.
Participants: all had chronic schizophrenia.
Intervention: examined the change in BPRS and SANS scores at three different serum clozapine levels
Outcomes: compared BPRS scores by serum clozapine level, and not by clozapine dose
VanderZwaag 1997 Allocation: random allocation.
Participants: all had chronic schizophrenia.
Intervention: examined the change in EEG at three different serum clozapine levels
Outcomes: compared BPRS scores by serum clozapine level, and not by clozapine dose
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Characteristics of studies awaiting assessment [ordered by study ID]
Abraham 1997
Methods Allocation: unclear, no details.
Blindness: double-blind, rated independently.
Duration: 16 weeks.
Setting: inpatient.
Participants Diagnosis: treatment resistant schizophrenia or schizoaffective disorder (DSM-III-R).
N = 30.
Age: 35 to 53 years.
Sex: M 17, F 13.
Racial origin: not stated.
Consent: signed informed consent.
History: Average length of illness: 24.9 years (range 16.1 to 33.7 years)
Interventions 1. Clozapine: dose 100 mg/day.
2. Clozapine: dose 300 mg/day.
3. Clozapine: dose 600 mg/day.
Outcomes None.
Notes This report presents additional results from the Simpson 1999 trial. Patients were allowed to adapt to new clinical
environment for minimum of four weeks, followed by four weeks of haloperidol treatment and a one-week wash-out
period. Participants who were randomised to 300 mg/day or 600 mg/day of clozapine were subsequently categorised
as “improvers” or “non-improvers” based on change in CGI scores, and these groups were compared on demographics,
baseline characteristics and BPRS scores. No information was given, however, on the dosage group to which the
improvers and non-improvers belonged. We contacted the lead author who agreed to send the missing data, but
at the time of writing this had not been received. If we subsequently receive this data, we will include it in future
versions of this review
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D A T A A N D A N A L Y S E S
Comparison 1. CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mental state: Average endpoint
score (BPRS-A, high = poor) -
medium term
1 31 Mean Difference (IV, Random, 95% CI) 3.55 [-4.50, 11.60]
2 Adverse effects: 1a. Weight -
BMI - short term
1 59 Mean Difference (IV, Random, 95% CI) -0.10 [-0.95, 0.75]
3 Adverse effects: 1b. Weight -
weight gain
1 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 short term 1 27 Mean Difference (IV, Random, 95% CI) -1.1 [-3.93, 1.73]
3.2 medium term 1 28 Mean Difference (IV, Random, 95% CI) -1.3 [-4.86, 2.26]
4 Adverse effects: 1c. Weight -
body weight at endpoint - short
term
1 59 Mean Difference (IV, Random, 95% CI) 0.0 [-3.92, 3.92]
5 Adverse effects: 2a. Metabolic -
blood glucose - short term
1 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Before meal 1 59 Mean Difference (IV, Random, 95% CI) -0.40 [-1.06, 0.26]
5.2 1 hour after meal 1 59 Mean Difference (IV, Random, 95% CI) -0.70 [-2.01, 0.61]
5.3 2 hours after meal 1 59 Mean Difference (IV, Random, 95% CI) 0.30 [-0.98, 1.58]
5.4 3 hours after meal 1 59 Mean Difference (IV, Random, 95% CI) -0.70 [-1.59, 0.19]
6 Adverse effects: 2b. Metabolic -
lipid profile - short term
1 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 triglycerides 1 59 Mean Difference (IV, Random, 95% CI) 1.00 [0.51, 1.49]
6.2 cholesterol - total 1 59 Mean Difference (IV, Random, 95% CI) 0.50 [-0.12, 1.12]
6.3 lipoprotein - high density
(HDL)
1 59 Mean Difference (IV, Random, 95% CI) 0.04 [-0.14, 0.22]
6.4 lipoprotein - low density
(LDL)
1 59 Mean Difference (IV, Random, 95% CI) 0.10 [-0.36, 0.56]
6.5 Apo A-1 1 59 Mean Difference (IV, Random, 95% CI) 0.05 [-0.10, 0.20]
6.6 Apo-B 1 59 Mean Difference (IV, Random, 95% CI) 0.13 [-0.16, 0.42]
7 Leaving the study early 2 91 Risk Ratio (M-H, Random, 95% CI) 1.50 [0.09, 25.41]
7.1 any reason - medium term 1 31 Risk Ratio (M-H, Random, 95% CI) 6.0 [0.31, 115.56]
7.2 specific reason (alanine
aminotransferase level) - short
term
1 60 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 7.87]
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Comparison 2. CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600
mg/day)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mental state: 1a. Average
endpoint score (BPRS-A, high
= poor) - medium term
1 31 Mean Difference (IV, Random, 95% CI) 6.67 [-2.09, 15.43]
2 Adverse effects: 1a. Weight -
BMI - short term
1 58 Mean Difference (IV, Random, 95% CI) 0.10 [-0.76, 0.96]
3 Adverse effects: 1b. Weight -
weight gain
1 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 short term 1 27 Mean Difference (IV, Random, 95% CI) -2.70 [-5.38, -0.02]
3.2 medium term 1 28 Mean Difference (IV, Random, 95% CI) -3.10 [-6.73, 0.53]
4 Adverse effects: 1c. Weight -
body weight at endpoint - short
term
1 58 Mean Difference (IV, Random, 95% CI) 1.0 [-2.66, 4.66]
5 Adverse effects: 2a. Metabolic -
blood glucose - short term
1 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 one hour after meal 1 58 Mean Difference (IV, Random, 95% CI) -1.60 [-2.90, -0.30]
5.2 before meal 1 58 Mean Difference (IV, Random, 95% CI) -0.10 [-0.68, 0.48]
5.3 two hours after meal 1 58 Mean Difference (IV, Random, 95% CI) -0.60 [-1.89, 0.69]
5.4 three hours after meal 1 58 Mean Difference (IV, Random, 95% CI) -0.30 [-1.55, 0.95]
6 Adverse effects: 2b. Metabolic -
lipid profile - short term
1 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 cholesterol - total 1 58 Mean Difference (IV, Random, 95% CI) 1.00 [0.20, 1.80]
6.2 triglycerides 1 58 Mean Difference (IV, Random, 95% CI) 1.30 [0.81, 1.79]
6.3 Apo - B 1 58 Mean Difference (IV, Random, 95% CI) 0.23 [0.01, 0.45]
6.4 lipoprotein - high density
(HDL)
1 58 Mean Difference (IV, Random, 95% CI) 0.10 [-0.13, 0.33]
6.5 lipoprotein - low density
(LDL)
1 58 Mean Difference (IV, Random, 95% CI) 0.0 [-0.39, 0.39]
6.6 Apo A -1 1 58 Mean Difference (IV, Random, 95% CI) 0.04 [-0.10, 0.18]
7 Leaving the study early 2 91 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.14, 3.72]
7.1 any reason - medium term 1 31 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.20, 7.55]
7.2 specific reason
(neutropenia and tachycardia) -
short term
1 60 Risk Ratio (M-H, Random, 95% CI) 0.2 [0.01, 4.00]
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Comparison 3. CLOZAPINE: LOWDOSE (150 to 300 mg/day) versus STANDARDDOSE (301 to 600 mg/day)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mental state: 1a. Clinically
important response as (BPRS
score > 30% change)
1 176 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.78, 1.10]
2 Mental state: 1b. Average
endpoint score (BPRS-A total,
high = poor)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 short term 1 176 Mean Difference (IV, Random, 95% CI) 1.70 [-1.26, 4.66]
2.2 medium term 1 34 Mean Difference (IV, Random, 95% CI) 3.12 [-4.20, 10.44]
3 Mental state: 1c. Average
endpoint score (BPRS-A
subscores, high = poor) - short
term
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 anxiety 1 176 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.09, 0.09]
3.2 blunted affect 1 176 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.18, 0.18]
3.3 conceptual disorganisation 1 176 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.02, 0.42]
3.4 excitement 1 176 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.10, 0.10]
3.5 uncooperativeness 1 176 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.21, 0.21]
4 Mental state: 1e. Clinical
improvement, clinician assessed
2 141 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.36, 1.61]
5 Adverse effects: 1a. Weight -
BMI - short term
1 57 Mean Difference (IV, Random, 95% CI) 0.20 [-0.84, 1.24]
6 Adverse effects: 1b. Weight -
weight gain
1 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 short term 1 165 Mean Difference (IV, Random, 95% CI) -1.60 [-3.81, 0.61]
6.2 medium term 1 30 Mean Difference (IV, Random, 95% CI) -1.80 [-5.38, 1.78]
7 Adverse effects: 1c. Weight -
body weight at endpoint - short
term
1 57 Mean Difference (IV, Random, 95% CI) 1.0 [-3.42, 5.42]
8 Adverse effects: 2a. Metabolic -
blood glucose - short term
1 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 before meal 1 57 Mean Difference (IV, Random, 95% CI) 0.30 [-0.23, 0.83]
8.2 one hour after meal 1 57 Mean Difference (IV, Random, 95% CI) -0.90 [-2.33, 0.53]
8.3 two hours after meal 1 58 Mean Difference (IV, Random, 95% CI) -0.90 [-2.14, 0.34]
8.4 three hours after meal 1 57 Mean Difference (IV, Random, 95% CI) 0.40 [-0.84, 1.64]
9 Adverse effects: 2b. Metabolic -
lipid profile - short term
1 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 cholesterol - total 1 57 Mean Difference (IV, Random, 95% CI) 0.5 [-0.29, 1.29]
9.2 triglycerides 1 57 Mean Difference (IV, Random, 95% CI) 0.30 [-0.12, 0.72]
9.3 lipoprotein - high density
(HDL)
1 57 Mean Difference (IV, Random, 95% CI) 0.06 [-0.16, 0.28]
9.4 lipoprotein - low density
(LDL)
1 57 Mean Difference (IV, Random, 95% CI) -0.10 [-0.50, 0.30]
9.5 Apo A -1 1 57 Mean Difference (IV, Random, 95% CI) -0.01 [-0.14, 0.12]
9.6 Apo - B 1 57 Mean Difference (IV, Random, 95% CI) 0.10 [-0.14, 0.34]
10 Adverse effects: 3. Various
effects - short term
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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10.1 lethargy 1 176 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.60, 0.97]
10.2 hypersalivation 1 176 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.57, 0.84]
10.3 dizziness 1 176 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.39, 0.81]
10.4 tachycardia 1 176 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.45, 0.71]
11 Adverse effects: 4. Average
endpoint scores (TESS, high =
poor) - short term
2 Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 total 2 266 Mean Difference (IV, Random, 95% CI) -3.99 [-5.75, -2.24]
11.2 subscore - behavioural
toxicity
1 176 Mean Difference (IV, Random, 95% CI) 1.00 [-1.51, -0.49]
11.3 subscore - vegetative
nervous system
1 176 Mean Difference (IV, Random, 95% CI) -0.90 [-1.61, -0.19]
11.4 subscore - cardiovascular
system
1 176 Mean Difference (IV, Random, 95% CI) -0.60 [-0.98, -0.22]
12 Leaving the study early 3 270 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.06, 2.21]
12.1 any reason: short term 1 176 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 any reason: medium
term
1 34 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.01, 3.88]
12.3 specific reason: short
term
1 60 Risk Ratio (M-H, Random, 95% CI) 0.5 [0.05, 5.22]
Analysis 1.1. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150
to 300 mg/day), Outcome 1 Mental state: Average endpoint score (BPRS-A, high = poor) - medium term.
Review: Clozapine dose for schizophrenia
Comparison: 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day)
Outcome: 1 Mental state: Average endpoint score (BPRS-A, high = poor) - medium term
Study or subgroup very low dose low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Simpson 1999 14 49.43 (12.65) 17 45.88 (9.61) 100.0 % 3.55 [ -4.50, 11.60 ]
Total (95% CI) 14 17 100.0 % 3.55 [ -4.50, 11.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
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Analysis 1.2. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150
to 300 mg/day), Outcome 2 Adverse effects: 1a. Weight - BMI - short term.
Review: Clozapine dose for schizophrenia
Comparison: 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day)
Outcome: 2 Adverse effects: 1a. Weight - BMI - short term
Study or subgroup very low dose low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Liu 2005 30 23.1 (1.2) 29 23.2 (2) 100.0 % -0.10 [ -0.95, 0.75 ]
Total (95% CI) 30 29 100.0 % -0.10 [ -0.95, 0.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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Analysis 1.3. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150
to 300 mg/day), Outcome 3 Adverse effects: 1b. Weight - weight gain.
Review: Clozapine dose for schizophrenia
Comparison: 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day)
Outcome: 3 Adverse effects: 1b. Weight - weight gain
Study or subgroup very low dose low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term
Simpson 1999 12 1.1 (3.3) 15 2.2 (4.2) 100.0 % -1.10 [ -3.93, 1.73 ]
Subtotal (95% CI) 12 15 100.0 % -1.10 [ -3.93, 1.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
2 medium term
Simpson 1999 13 1.3 (4.7) 15 2.6 (4.9) 100.0 % -1.30 [ -4.86, 2.26 ]
Subtotal (95% CI) 13 15 100.0 % -1.30 [ -4.86, 2.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
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Analysis 1.4. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150
to 300 mg/day), Outcome 4 Adverse effects: 1c. Weight - body weight at endpoint - short term.
Review: Clozapine dose for schizophrenia
Comparison: 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day)
Outcome: 4 Adverse effects: 1c. Weight - body weight at endpoint - short term
Study or subgroup very low dose low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Liu 2005 30 69 (6) 29 69 (9) 100.0 % 0.0 [ -3.92, 3.92 ]
Total (95% CI) 30 29 100.0 % 0.0 [ -3.92, 3.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 1.5. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150
to 300 mg/day), Outcome 5 Adverse effects: 2a. Metabolic - blood glucose - short term.
Review: Clozapine dose for schizophrenia
Comparison: 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day)
Outcome: 5 Adverse effects: 2a. Metabolic - blood glucose - short term
Study or subgroup very low dose low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Before meal
Liu 2005 30 4.7 (1.4) 29 5.1 (1.2) 100.0 % -0.40 [ -1.06, 0.26 ]
Subtotal (95% CI) 30 29 100.0 % -0.40 [ -1.06, 0.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
2 1 hour after meal
Liu 2005 30 8.1 (2.3) 29 8.8 (2.8) 100.0 % -0.70 [ -2.01, 0.61 ]
Subtotal (95% CI) 30 29 100.0 % -0.70 [ -2.01, 0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
3 2 hours after meal
Liu 2005 30 7.3 (2.6) 29 7 (2.4) 100.0 % 0.30 [ -0.98, 1.58 ]
Subtotal (95% CI) 30 29 100.0 % 0.30 [ -0.98, 1.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
4 3 hours after meal
Liu 2005 30 5.5 (1.8) 29 6.2 (1.7) 100.0 % -0.70 [ -1.59, 0.19 ]
Subtotal (95% CI) 30 29 100.0 % -0.70 [ -1.59, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Chi2 = 1.78, df = 3 (P = 0.62), I2 =0.0%
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Analysis 1.6. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150
to 300 mg/day), Outcome 6 Adverse effects: 2b. Metabolic - lipid profile - short term.
Review: Clozapine dose for schizophrenia
Comparison: 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day)
Outcome: 6 Adverse effects: 2b. Metabolic - lipid profile - short term
Study or subgroup very low dose low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 triglycerides
Liu 2005 30 2.7 (1.1) 29 1.7 (0.8) 100.0 % 1.00 [ 0.51, 1.49 ]
Subtotal (95% CI) 30 29 100.0 % 1.00 [ 0.51, 1.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.00 (P = 0.000063)
2 cholesterol - total
Liu 2005 30 4.4 (1.1) 29 3.9 (1.3) 100.0 % 0.50 [ -0.12, 1.12 ]
Subtotal (95% CI) 30 29 100.0 % 0.50 [ -0.12, 1.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
3 lipoprotein - high density (HDL)
Liu 2005 30 1.03 (0.37) 29 0.99 (0.34) 100.0 % 0.04 [ -0.14, 0.22 ]
Subtotal (95% CI) 30 29 100.0 % 0.04 [ -0.14, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
4 lipoprotein - low density (LDL)
Liu 2005 30 2.2 (0.9) 29 2.1 (0.9) 100.0 % 0.10 [ -0.36, 0.56 ]
Subtotal (95% CI) 30 29 100.0 % 0.10 [ -0.36, 0.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
5 Apo A-1
Liu 2005 30 0.94 (0.31) 29 0.89 (0.29) 100.0 % 0.05 [ -0.10, 0.20 ]
Subtotal (95% CI) 30 29 100.0 % 0.05 [ -0.10, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
6 Apo-B
Liu 2005 30 1.03 (0.56) 29 0.9 (0.59) 100.0 % 0.13 [ -0.16, 0.42 ]
Subtotal (95% CI) 30 29 100.0 % 0.13 [ -0.16, 0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
Test for subgroup differences: Chi2 = 15.42, df = 5 (P = 0.01), I2 =68%
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Analysis 1.7. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150
to 300 mg/day), Outcome 7 Leaving the study early.
Review: Clozapine dose for schizophrenia
Comparison: 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day)
Outcome: 7 Leaving the study early
Study or subgroup very low dose low dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any reason - medium term
Simpson 1999 2/14 0/17 51.9 % 6.00 [ 0.31, 115.56 ]
Subtotal (95% CI) 14 17 51.9 % 6.00 [ 0.31, 115.56 ]
Total events: 2 (very low dose), 0 (low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.24)
2 specific reason (alanine aminotransferase level) - short term
Liu 2005 0/30 1/30 48.1 % 0.33 [ 0.01, 7.87 ]
Subtotal (95% CI) 30 30 48.1 % 0.33 [ 0.01, 7.87 ]
Total events: 0 (very low dose), 1 (low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI) 44 47 100.0 % 1.50 [ 0.09, 25.41 ]
Total events: 2 (very low dose), 1 (low dose)
Heterogeneity: Tau2 = 1.74; Chi2 = 1.71, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Chi2 = 1.71, df = 1 (P = 0.19), I2 =42%
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Analysis 2.1. Comparison 2 CLOZAPINE: VERY LOWDOSE (up to 149 mg/day) versus STANDARD DOSE
(301-600 mg/day), Outcome 1 Mental state: 1a. Average endpoint score (BPRS-A, high = poor) - medium term.
Review: Clozapine dose for schizophrenia
Comparison: 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day)
Outcome: 1 Mental state: 1a. Average endpoint score (BPRS-A, high = poor) - medium term
Study or subgroup very low dose standard dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Simpson 1999 14 49.43 (12.65) 17 42.76 (12.04) 100.0 % 6.67 [ -2.09, 15.43 ]
Total (95% CI) 14 17 100.0 % 6.67 [ -2.09, 15.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 CLOZAPINE: VERY LOWDOSE (up to 149 mg/day) versus STANDARD DOSE
(301-600 mg/day), Outcome 2 Adverse effects: 1a. Weight - BMI - short term.
Review: Clozapine dose for schizophrenia
Comparison: 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day)
Outcome: 2 Adverse effects: 1a. Weight - BMI - short term
Study or subgroup very low dose standard dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Liu 2005 30 23.1 (1.2) 28 23 (2) 100.0 % 0.10 [ -0.76, 0.96 ]
Total (95% CI) 30 28 100.0 % 0.10 [ -0.76, 0.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 CLOZAPINE: VERY LOWDOSE (up to 149 mg/day) versus STANDARD DOSE
(301-600 mg/day), Outcome 3 Adverse effects: 1b. Weight - weight gain.
Review: Clozapine dose for schizophrenia
Comparison: 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day)
Outcome: 3 Adverse effects: 1b. Weight - weight gain
Study or subgroup very low dose standard dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term
Simpson 1999 12 1.1 (3.3) 15 3.8 (3.8) 100.0 % -2.70 [ -5.38, -0.02 ]
Subtotal (95% CI) 12 15 100.0 % -2.70 [ -5.38, -0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.048)
2 medium term
Simpson 1999 13 1.3 (4.7) 15 4.4 (5.1) 100.0 % -3.10 [ -6.73, 0.53 ]
Subtotal (95% CI) 13 15 100.0 % -3.10 [ -6.73, 0.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.094)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
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Analysis 2.4. Comparison 2 CLOZAPINE: VERY LOWDOSE (up to 149 mg/day) versus STANDARD DOSE
(301-600 mg/day), Outcome 4 Adverse effects: 1c. Weight - body weight at endpoint - short term.
Review: Clozapine dose for schizophrenia
Comparison: 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day)
Outcome: 4 Adverse effects: 1c. Weight - body weight at endpoint - short term
Study or subgroup very low dose standard dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Liu 2005 30 69 (6) 28 68 (8) 100.0 % 1.00 [ -2.66, 4.66 ]
Total (95% CI) 30 28 100.0 % 1.00 [ -2.66, 4.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 CLOZAPINE: VERY LOWDOSE (up to 149 mg/day) versus STANDARD DOSE
(301-600 mg/day), Outcome 5 Adverse effects: 2a. Metabolic - blood glucose - short term.
Review: Clozapine dose for schizophrenia
Comparison: 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day)
Outcome: 5 Adverse effects: 2a. Metabolic - blood glucose - short term
Study or subgroup very low dose standard dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 one hour after meal
Liu 2005 30 8.1 (2.3) 28 9.7 (2.7) 100.0 % -1.60 [ -2.90, -0.30 ]
Subtotal (95% CI) 30 28 100.0 % -1.60 [ -2.90, -0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.015)
2 before meal
Liu 2005 30 4.7 (1.4) 28 4.8 (0.8) 100.0 % -0.10 [ -0.68, 0.48 ]
Subtotal (95% CI) 30 28 100.0 % -0.10 [ -0.68, 0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
3 two hours after meal
Liu 2005 30 7.3 (2.6) 28 7.9 (2.4) 100.0 % -0.60 [ -1.89, 0.69 ]
Subtotal (95% CI) 30 28 100.0 % -0.60 [ -1.89, 0.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
4 three hours after meal
Liu 2005 30 5.5 (1.8) 28 5.8 (2.9) 100.0 % -0.30 [ -1.55, 0.95 ]
Subtotal (95% CI) 30 28 100.0 % -0.30 [ -1.55, 0.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 4.43, df = 3 (P = 0.22), I2 =32%
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Analysis 2.6. Comparison 2 CLOZAPINE: VERY LOWDOSE (up to 149 mg/day) versus STANDARD DOSE
(301-600 mg/day), Outcome 6 Adverse effects: 2b. Metabolic - lipid profile - short term.
Review: Clozapine dose for schizophrenia
Comparison: 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day)
Outcome: 6 Adverse effects: 2b. Metabolic - lipid profile - short term
Study or subgroup very low dose standard dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 cholesterol - total
Liu 2005 30 4.4 (1.4) 28 3.4 (1.7) 100.0 % 1.00 [ 0.20, 1.80 ]
Subtotal (95% CI) 30 28 100.0 % 1.00 [ 0.20, 1.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.015)
2 triglycerides
Liu 2005 30 2.7 (1.1) 28 1.4 (0.8) 100.0 % 1.30 [ 0.81, 1.79 ]
Subtotal (95% CI) 30 28 100.0 % 1.30 [ 0.81, 1.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.17 (P < 0.00001)
3 Apo - B
Liu 2005 30 1.03 (0.56) 28 0.8 (0.26) 100.0 % 0.23 [ 0.01, 0.45 ]
Subtotal (95% CI) 30 28 100.0 % 0.23 [ 0.01, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.043)
4 lipoprotein - high density (HDL)
Liu 2005 30 1.03 (0.37) 28 0.93 (0.5) 100.0 % 0.10 [ -0.13, 0.33 ]
Subtotal (95% CI) 30 28 100.0 % 0.10 [ -0.13, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
5 lipoprotein - low density (LDL)
Liu 2005 30 2.2 (0.9) 28 2.2 (0.6) 100.0 % 0.0 [ -0.39, 0.39 ]
Subtotal (95% CI) 30 28 100.0 % 0.0 [ -0.39, 0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
6 Apo A -1
Liu 2005 30 0.94 (0.31) 28 0.9 (0.22) 100.0 % 0.04 [ -0.10, 0.18 ]
Subtotal (95% CI) 30 28 100.0 % 0.04 [ -0.10, 0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Chi2 = 28.92, df = 5 (P = 0.00), I2 =83%
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Analysis 2.7. Comparison 2 CLOZAPINE: VERY LOWDOSE (up to 149 mg/day) versus STANDARD DOSE
(301-600 mg/day), Outcome 7 Leaving the study early.
Review: Clozapine dose for schizophrenia
Comparison: 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day)
Outcome: 7 Leaving the study early
Study or subgroup very low dose standard dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any reason - medium term
Simpson 1999 2/14 2/17 71.5 % 1.21 [ 0.20, 7.55 ]
Subtotal (95% CI) 14 17 71.5 % 1.21 [ 0.20, 7.55 ]
Total events: 2 (very low dose), 2 (standard dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.84)
2 specific reason (neutropenia and tachycardia) - short term
Liu 2005 0/30 2/30 28.5 % 0.20 [ 0.01, 4.00 ]
Subtotal (95% CI) 30 30 28.5 % 0.20 [ 0.01, 4.00 ]
Total events: 0 (very low dose), 2 (standard dose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Total (95% CI) 44 47 100.0 % 0.73 [ 0.14, 3.72 ]
Total events: 2 (very low dose), 4 (standard dose)
Heterogeneity: Tau2 = 0.10; Chi2 = 1.06, df = 1 (P = 0.30); I2 =6%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Chi2 = 1.01, df = 1 (P = 0.31), I2 =1%
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Analysis 3.1. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301
to 600 mg/day), Outcome 1 Mental state: 1a. Clinically important response as (BPRS score > 30% change).
Review: Clozapine dose for schizophrenia
Comparison: 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day)
Outcome: 1 Mental state: 1a. Clinically important response as (BPRS score > 30% change)
Study or subgroup low dose standard dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chen 1998 68/94 64/82 100.0 % 0.93 [ 0.78, 1.10 ]
Total (95% CI) 94 82 100.0 % 0.93 [ 0.78, 1.10 ]
Total events: 68 (low dose), 64 (standard dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301
to 600 mg/day), Outcome 2 Mental state: 1b. Average endpoint score (BPRS-A total, high = poor).
Review: Clozapine dose for schizophrenia
Comparison: 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day)
Outcome: 2 Mental state: 1b. Average endpoint score (BPRS-A total, high = poor)
Study or subgroup low dose standard dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term
Chen 1998 94 30.9 (11.7) 82 29.2 (8.2) 100.0 % 1.70 [ -1.26, 4.66 ]
Subtotal (95% CI) 94 82 100.0 % 1.70 [ -1.26, 4.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
2 medium term
Simpson 1999 17 45.88 (9.61) 17 42.76 (12.04) 100.0 % 3.12 [ -4.20, 10.44 ]
Subtotal (95% CI) 17 17 100.0 % 3.12 [ -4.20, 10.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 0.12, df = 1 (P = 0.72), I2 =0.0%
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Analysis 3.3. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301
to 600 mg/day), Outcome 3 Mental state: 1c. Average endpoint score (BPRS-A subscores, high = poor) - short
term.
Review: Clozapine dose for schizophrenia
Comparison: 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day)
Outcome: 3 Mental state: 1c. Average endpoint score (BPRS-A subscores, high = poor) - short term
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 anxiety
Chen 1998 94 1.2 (0.3) 82 1.2 (0.3) 100.0 % 0.0 [ -0.09, 0.09 ]
Subtotal (95% CI) 94 82 100.0 % 0.0 [ -0.09, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 blunted affect
Chen 1998 94 1.6 (0.6) 82 1.6 (0.6) 100.0 % 0.0 [ -0.18, 0.18 ]
Subtotal (95% CI) 94 82 100.0 % 0.0 [ -0.18, 0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 conceptual disorganisation
Chen 1998 94 1.9 (0.8) 82 1.7 (0.7) 100.0 % 0.20 [ -0.02, 0.42 ]
Subtotal (95% CI) 94 82 100.0 % 0.20 [ -0.02, 0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
4 excitement
Chen 1998 94 1.1 (0.4) 82 1.1 (0.3) 100.0 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 94 82 100.0 % 0.0 [ -0.10, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 uncooperativeness
Chen 1998 94 1.5 (0.7) 82 1.5 (0.7) 100.0 % 0.0 [ -0.21, 0.21 ]
Subtotal (95% CI) 94 82 100.0 % 0.0 [ -0.21, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 2.91, df = 4 (P = 0.57), I2 =0.0%
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Analysis 3.4. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301
to 600 mg/day), Outcome 4 Mental state: 1e. Clinical improvement, clinician assessed.
Review: Clozapine dose for schizophrenia
Comparison: 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day)
Outcome: 4 Mental state: 1e. Clinical improvement, clinician assessed
Study or subgroup Low dose Standard dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chen 2013 15/30 51/60 47.4 % 0.59 [ 0.40, 0.85 ]
Sheng 1990 23/25 25/26 52.6 % 0.96 [ 0.83, 1.10 ]
Total (95% CI) 55 86 100.0 % 0.76 [ 0.36, 1.61 ]
Total events: 38 (Low dose), 76 (Standard dose)
Heterogeneity: Tau2 = 0.27; Chi2 = 14.30, df = 1 (P = 0.00016); I2 =93%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301
to 600 mg/day), Outcome 5 Adverse effects: 1a. Weight - BMI - short term.
Review: Clozapine dose for schizophrenia
Comparison: 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day)
Outcome: 5 Adverse effects: 1a. Weight - BMI - short term
Study or subgroup low dose standard dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Liu 2005 29 23.2 (2) 28 23 (2) 100.0 % 0.20 [ -0.84, 1.24 ]
Total (95% CI) 29 28 100.0 % 0.20 [ -0.84, 1.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301
to 600 mg/day), Outcome 6 Adverse effects: 1b. Weight - weight gain.
Review: Clozapine dose for schizophrenia
Comparison: 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day)
Outcome: 6 Adverse effects: 1b. Weight - weight gain
Study or subgroup low dose standard dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term
Simpson 1999 15 2.2 (4.2) 150 3.8 (3.8) 100.0 % -1.60 [ -3.81, 0.61 ]
Subtotal (95% CI) 15 150 100.0 % -1.60 [ -3.81, 0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
2 medium term
Simpson 1999 15 2.6 (4.9) 15 4.4 (5.1) 100.0 % -1.80 [ -5.38, 1.78 ]
Subtotal (95% CI) 15 15 100.0 % -1.80 [ -5.38, 1.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
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Analysis 3.7. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301
to 600 mg/day), Outcome 7 Adverse effects: 1c. Weight - body weight at endpoint - short term.
Review: Clozapine dose for schizophrenia
Comparison: 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day)
Outcome: 7 Adverse effects: 1c. Weight - body weight at endpoint - short term
Study or subgroup low dose standard dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Liu 2005 29 69 (9) 28 68 (8) 100.0 % 1.00 [ -3.42, 5.42 ]
Total (95% CI) 29 28 100.0 % 1.00 [ -3.42, 5.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301
to 600 mg/day), Outcome 8 Adverse effects: 2a. Metabolic - blood glucose - short term.
Review: Clozapine dose for schizophrenia
Comparison: 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day)
Outcome: 8 Adverse effects: 2a. Metabolic - blood glucose - short term
Study or subgroup low dose standard dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 before meal
Liu 2005 29 5.1 (1.2) 28 4.8 (0.8) 100.0 % 0.30 [ -0.23, 0.83 ]
Subtotal (95% CI) 29 28 100.0 % 0.30 [ -0.23, 0.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
2 one hour after meal
Liu 2005 29 8.8 (2.8) 28 9.7 (2.7) 100.0 % -0.90 [ -2.33, 0.53 ]
Subtotal (95% CI) 29 28 100.0 % -0.90 [ -2.33, 0.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
3 two hours after meal
Liu 2005 29 7 (2.4) 29 7.9 (2.4) 100.0 % -0.90 [ -2.14, 0.34 ]
Subtotal (95% CI) 29 29 100.0 % -0.90 [ -2.14, 0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
4 three hours after meal
Liu 2005 29 6.2 (1.7) 28 5.8 (2.9) 100.0 % 0.40 [ -0.84, 1.64 ]
Subtotal (95% CI) 29 28 100.0 % 0.40 [ -0.84, 1.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Chi2 = 5.14, df = 3 (P = 0.16), I2 =42%
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Analysis 3.9. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301
to 600 mg/day), Outcome 9 Adverse effects: 2b. Metabolic - lipid profile - short term.
Review: Clozapine dose for schizophrenia
Comparison: 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day)
Outcome: 9 Adverse effects: 2b. Metabolic - lipid profile - short term
Study or subgroup low dose standard dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 cholesterol - total
Liu 2005 29 3.9 (1.3) 28 3.4 (1.7) 100.0 % 0.50 [ -0.29, 1.29 ]
Subtotal (95% CI) 29 28 100.0 % 0.50 [ -0.29, 1.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.21)
2 triglycerides
Liu 2005 29 1.7 (0.8) 28 1.4 (0.8) 100.0 % 0.30 [ -0.12, 0.72 ]
Subtotal (95% CI) 29 28 100.0 % 0.30 [ -0.12, 0.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
3 lipoprotein - high density (HDL)
Liu 2005 29 0.99 (0.34) 28 0.93 (0.5) 100.0 % 0.06 [ -0.16, 0.28 ]
Subtotal (95% CI) 29 28 100.0 % 0.06 [ -0.16, 0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
4 lipoprotein - low density (LDL)
Liu 2005 29 2.1 (0.9) 28 2.2 (0.6) 100.0 % -0.10 [ -0.50, 0.30 ]
Subtotal (95% CI) 29 28 100.0 % -0.10 [ -0.50, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
5 Apo A -1
Liu 2005 29 0.89 (0.29) 28 0.9 (0.22) 100.0 % -0.01 [ -0.14, 0.12 ]
Subtotal (95% CI) 29 28 100.0 % -0.01 [ -0.14, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
6 Apo - B
Liu 2005 29 0.9 (0.59) 28 0.8 (0.26) 100.0 % 0.10 [ -0.14, 0.34 ]
Subtotal (95% CI) 29 28 100.0 % 0.10 [ -0.14, 0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.40)
Test for subgroup differences: Chi2 = 4.12, df = 5 (P = 0.53), I2 =0.0%
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Analysis 3.10. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE
(301 to 600 mg/day), Outcome 10 Adverse effects: 3. Various effects - short term.
Review: Clozapine dose for schizophrenia
Comparison: 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day)
Outcome: 10 Adverse effects: 3. Various effects - short term
Study or subgroup low dose standard dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 lethargy
Chen 1998 50/94 57/82 100.0 % 0.77 [ 0.60, 0.97 ]
Subtotal (95% CI) 94 82 100.0 % 0.77 [ 0.60, 0.97 ]
Total events: 50 (low dose), 57 (standard dose)
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
2 hypersalivation
Chen 1998 55/94 69/82 100.0 % 0.70 [ 0.57, 0.84 ]
Subtotal (95% CI) 94 82 100.0 % 0.70 [ 0.57, 0.84 ]
Total events: 55 (low dose), 69 (standard dose)
Heterogeneity: not applicable
Test for overall effect: Z = 3.66 (P = 0.00025)
3 dizziness
Chen 1998 29/94 45/82 100.0 % 0.56 [ 0.39, 0.81 ]
Subtotal (95% CI) 94 82 100.0 % 0.56 [ 0.39, 0.81 ]
Total events: 29 (low dose), 45 (standard dose)
Heterogeneity: not applicable
Test for overall effect: Z = 3.13 (P = 0.0018)
4 tachycardia
Chen 1998 46/94 71/82 100.0 % 0.57 [ 0.45, 0.71 ]
Subtotal (95% CI) 94 82 100.0 % 0.57 [ 0.45, 0.71 ]
Total events: 46 (low dose), 71 (standard dose)
Heterogeneity: not applicable
Test for overall effect: Z = 5.01 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.37, df = 3 (P = 0.22), I2 =31%
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Analysis 3.11. Comparison 3 CLOZAPINE: LOWDOSE (150 to 300 mg/day) versus STANDARD DOSE (301
to 600 mg/day), Outcome 11 Adverse effects: 4. Average endpoint scores (TESS, high = poor) - short term.
Review: Clozapine dose for schizophrenia
Comparison: 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day)
Outcome: 11 Adverse effects: 4. Average endpoint scores (TESS, high = poor) - short term
Study or subgroup low dose standard dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 total
Chen 1998 94 7.5 (8.8) 82 10.5 (8.8) 45.0 % -3.00 [ -5.61, -0.39 ]
Chen 2013 30 8.5 (4.9) 60 13.3 (6.2) 55.0 % -4.80 [ -7.15, -2.45 ]
Subtotal (95% CI) 124 142 100.0 % -3.99 [ -5.75, -2.24 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 1.01, df = 1 (P = 0.32); I2 =1%
Test for overall effect: Z = 4.46 (P < 0.00001)
2 subscore - behavioural toxicity
Chen 1998 94 0.9 (1.1) 82 1.9 (2.1) 100.0 % -1.00 [ -1.51, -0.49 ]
Subtotal (95% CI) 94 82 100.0 % -1.00 [ -1.51, -0.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.87 (P = 0.00011)
3 subscore - vegetative nervous system
Chen 1998 94 3.6 (2.7) 82 4.5 (2.1) 100.0 % -0.90 [ -1.61, -0.19 ]
Subtotal (95% CI) 94 82 100.0 % -0.90 [ -1.61, -0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.013)
4 subscore - cardiovascular system
Chen 1998 94 1.5 (1.1) 82 2.1 (1.4) 100.0 % -0.60 [ -0.98, -0.22 ]
Subtotal (95% CI) 94 82 100.0 % -0.60 [ -0.98, -0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.13 (P = 0.0018)
Test for subgroup differences: Chi2 = 14.36, df = 3 (P = 0.00), I2 =79%
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Analysis 3.12. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE
(301 to 600 mg/day), Outcome 12 Leaving the study early.
Review: Clozapine dose for schizophrenia
Comparison: 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day)
Outcome: 12 Leaving the study early
Study or subgroup low dose standard dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any reason: short term
Chen 1998 0/94 0/82 Not estimable
Subtotal (95% CI) 94 82 Not estimable
Total events: 0 (low dose), 0 (standard dose)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 any reason: medium term
Simpson 1999 0/17 2/17 38.5 % 0.20 [ 0.01, 3.88 ]
Subtotal (95% CI) 17 17 38.5 % 0.20 [ 0.01, 3.88 ]
Total events: 0 (low dose), 2 (standard dose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
3 specific reason: short term
Liu 2005 1/30 2/30 61.5 % 0.50 [ 0.05, 5.22 ]
Subtotal (95% CI) 30 30 61.5 % 0.50 [ 0.05, 5.22 ]
Total events: 1 (low dose), 2 (standard dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Total (95% CI) 141 129 100.0 % 0.35 [ 0.06, 2.21 ]
Total events: 1 (low dose), 4 (standard dose)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
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A D D I T I O N A L T A B L E S
Table 1. Other reviews in the clozapine series
Title Reference
Clozapine versus other atypical antipsychotics for schizophrenia Asenjo 2010
Clozapine combined with different antipsychotic drugs for treat-
ment resistant schizophrenia
Cipriani 2009
Clozapine versus typical neuroleptic medication for schizophrenia Essali 2009
Pharmacological interventions for clozapine-induced hypersaliva-
tion
Syed 2008
A P P E N D I C E S
Appendix 1. Previous searches
Search in 2011
Electronic searches
Cochrane Schizophrenia Group Trials Register
We searched the register (August 2011) using the following phrase:
[(*clozapin* or *clozaril* or *leponex* or *denzapin* or *zaponex* in intervention of STUDY) AND (*dose* or *dosage* or *dosage?
effect* or *dose?activity* or *dose?dependence* or *dose?effect* or *dose?rate* or *dose?response* or *dosage?scheme* or *drug?response*
or *effective?dose* or *dose?finding* or *dose?calculation* or *therapeutic?equiv* or *blood?level* or *blood?drug* or *serum?level* or
*serum?drug* or *plasma-level* or *plasma-drug* or *high?dos* or *low?dos* or *medium?dos* or *standard?dos* or *middle?dos* or
*maximum?dos* or *minimum?dos* or *threshold?dos* in title abstract and index terms of reference)]
This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see group module).
Searching other resources
1. Reference searching
We searched the reference lists of each included paper, but failed find any new studies.
2. Personal contact
Where possible, we contacted the first author of trials or citations for missing information on unpublished data or trials.Where the
first author’s contact was not possible through the Cochrane Schizophrenia group, we attempted to contact the other authors. At the
time of writing, we have not received any of the missing data we requested, though one author indicated he will send the requested
information in future. We have discussed this in detail under relevant sections of results.
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H I S T O R Y
Protocol first published: Issue 1, 2012
Review first published: Issue 6, 2017
Date Event Description
8 December 2016 Amended Searchwas undertaken and 8 studies (13 references) added to ’Studies awaiting classification’ section
of the review. One study (Abraham 1997) already was in this section from last update.
C O N T R I B U T I O N S O F A U T H O R S
Selvizhi Subramanian - protocol development, study selection, data collection and synthesis, report writing.
Birgit A V llm - protocol development, study selection, data collection and synthesis, report writing.
Nick Huband - data synthesis, report writing.
D E C L A R A T I O N S O F I N T E R E S T
Selvizhi Subramanian - none known.
Birgit A V llm - none known.
Nick Huband - none known.
S O U R C E S O F S U P P O R T
Internal sources
• none, Other.
External sources
• none, Other.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The original categorisation of doses of clozapine was slightly changed to enable us to accommodate the doses compared in the trials of
the four included papers.
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